Page last updated: 2024-12-11

valproate sodium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Epilim: oral sodium valproate used as antidepressive agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

sodium valproate : The sodium salt of valproic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

valproate : A branched-chain saturated fatty acid anion that is the conjugate base of valproic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID16760703
CHEMBL ID433
CHEBI ID9925
SCHEMBL ID35027
MeSH IDM0022500

Synonyms (138)

Synonym
nsc 757376
unii-5vom6gyj0d
valproate sodium [usan:usp]
5vom6gyj0d ,
nsc 732626
CHEBI:9925 ,
sodium 2-propylpentanoate
sodium valproate
2-propylvaleric acid sodium salt
epilim
abbott 44090
EU-0100889
valproic acid sodium salt, 98%
valproate sodium
NCGC00016192-01
lopac-p-4543
valproate
selenica (tn)
1069-66-5
sodium valproate (jp17)
depakene (tn)
valproate sodium (usan)
D00710
valproic acid, sodium salt
NCGC00094208-03
NCGC00094208-02
eurekene
sodium dipropylacetate
natrium valproat
valproic acid sodium salt (1:1)
valproinsaeure, natrium
valproate sodium [usan]
labazene
valerin
depacon
valeric acid, 2-propyl-, sodium salt
dipropylacetate sodium
pentanoic acid, 2-propyl-, sodium salt
einecs 213-961-8
sodium n-dipropylacetate
sodium bispropylacetate
orfiril
sodium 2-n-propyl-pentanoate
kw 6066n
sodium 2-propylvalerate
2-propylpentanoic acid sodium salt
SPECTRUM1500606
nsc-732626
valproic acid sodium salt
NCGC00167849-01
NCGC00094208-01
valproic acid sodium
MLS001332432
smr000875243
MLS001332431
MLS002153189
NCGC00016192-02
2-propylpentanoic acid sodium
HMS2092C12
P 4543
a-44090
nsc-757376
CHEMBL433 ,
kw-6066n
abbott-44090
selenica
valproic acid, sodium
natrii valproas
HMS500N15
AKOS005066057
HMS1921I21
HMS3262B20
cas-1069-66-5
NCGC00256651-01
dtxcid3017072
dtxsid5037072 ,
tox21_302623
valproic acid sodium salt (sodium valproate)
HMS2230E16
CCG-40071
NCGC00016192-04
NCGC00016192-03
BCP0726000316
FT-0633278
LP00889
S1168
HMS3369L11
valproate sodium [orange book]
sodium 2-propylpentanoate [who-ip]
valproate sodium [who-dd]
sodium valproate [jan]
valproate sodium [usp impurity]
valproate sodium [vandf]
sodium valproate [ep monograph]
valproic acid sodium salt (1:1) [mi]
natrii valproas [who-ip latin]
sodium valproate [who-ip]
sodium valproate [mart.]
CCG-208088
valproic acid (sodium)
valproic acid (sodium salt)
HY-10585A
CS-1764
S0894
SCHEMBL35027
tox21_500889
NCGC00261574-01
AEQFSUDEHCCHBT-UHFFFAOYSA-M
Q-201918
HB0867
HMS3648A12
mfcd00078604
AC-8391
HMS3654I14
sodium valproate, european pharmacopoeia (ep) reference standard
sodium valproate, british pharmacopoeia (bp) reference standard
SW219169-2
Q4347890
valproic acid, sodium salt - cas 1069-66-5
SY058189
pentanoic acid, 2-propyl-, sodium salt (1:1)
AS-13150
BCP02888
HMS3872G13
HMS3884E05
CCG-266330
H11308
sodium valproate, 2-propylpentanoic acid . na, sodium 2-propylpentanoate
sodium;2-propylpentanoate
2-propyl-pentanoic acid, sodium salt
2-propylpentanoic acid sodium salt (1:1)
valproicacidsodium
EN300-7366609
sodium valproate (ep monograph)
monosodium 2-propylpentanoate
valproate sodium (usan:usp)
sodium valproate (mart.)
valproate sodium (usp impurity)

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" VPA half-life calculated from the urine data of the metabolite was shorter than the half-life calculated from the blood data."( Pharmacokinetics of valproic acid in volunteers after a single dose study.
Abramsky, O; Bialer, M; Herishanu, Y; Hussein, Z; Pachys, F; Raz, I,
)
0.13
" This study describes synthesis and stereospecific comparative pharmacodynamics (PD, anticonvulsant activity and teratogenicity) and pharmacokinetic (PK) analysis of four individual SPD stereoisomers."( Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
Bialer, M; Finnell, RH; Hen, N; McDonough, JH; Shekh-Ahmad, T; Wlodarczyk, B; Yagen, B, 2013
)
0.39

Dosage Studied

ExcerptRelevanceReference
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
organic sodium salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (52)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency42.28410.100020.879379.4328AID588453
RAR-related orphan receptor gammaMus musculus (house mouse)Potency18.14620.006038.004119,952.5996AID1159521; AID1159523
Fumarate hydrataseHomo sapiens (human)Potency3.98110.00308.794948.0869AID1347053
NFKB1 protein, partialHomo sapiens (human)Potency2.81840.02827.055915.8489AID895; AID928
AR proteinHomo sapiens (human)Potency36.20640.000221.22318,912.5098AID1259243
thyroid stimulating hormone receptorHomo sapiens (human)Potency39.81070.001318.074339.8107AID926; AID938
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency34.13580.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency48.36200.001530.607315,848.9004AID1224848; AID1224849
polyproteinZika virusPotency3.98110.00308.794948.0869AID1347053
aryl hydrocarbon receptorHomo sapiens (human)Potency64.38510.000723.06741,258.9301AID743085
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.00010.540617.639296.1227AID2364; AID2528
DNA polymerase kappa isoform 1Homo sapiens (human)Potency21.19230.031622.3146100.0000AID588579
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency1.58490.031610.279239.8107AID884; AID885
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency3.16230.251215.843239.8107AID504327
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency7.94330.00106.000935.4813AID944
neuropeptide S receptor isoform AHomo sapiens (human)Potency0.02000.015812.3113615.5000AID1461
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit piHomo sapiens (human)Ki100.00000.00090.89545.6234AID71287
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Ki100.00000.00020.656110.0000AID71568
Gamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)Ki100.00000.00090.89545.6234AID71287
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)IC50 (µMol)380.00000.00041.877310.0000AID34964
Leukotriene A-4 hydrolaseHomo sapiens (human)IC50 (µMol)10.00000.00051.28547.6500AID1441630; AID1441631
Gamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)Ki100.00000.00000.21085.6234AID71287
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Ki100.00000.00020.656110.0000AID71568
Gamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)Ki100.00000.00090.83985.6234AID71287
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Ki100.00000.00020.656110.0000AID71568
Gamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)Ki100.00000.00000.18819.0000AID71287
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Ki100.00000.00020.561410.0000AID71568
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Ki100.00000.00020.635210.0000AID71568
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Ki100.00000.00020.621710.0000AID71568
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Ki100.00000.00020.675810.0000AID71568
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Ki100.00000.00020.646910.0000AID71568
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Ki100.00000.00020.656110.0000AID71568
Gamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)Ki100.00000.00010.20769.0000AID71287
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Ki100.00000.00020.656110.0000AID71568
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Ki100.00000.00020.671210.0000AID71568
Gamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)Ki100.00000.00010.24425.6234AID71287
Gamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)Ki100.00000.00010.25155.6234AID71287
Gamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)Ki100.00000.00010.24015.6234AID71287
Gamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)Ki100.00000.00000.28325.6234AID71287
Gamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)Ki100.00000.00020.37095.6234AID71287
Aldo-keto reductase family 1 member A1Sus scrofa (pig)IC50 (µMol)89.00000.00051.66804.0000AID34179
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Ki100.00000.00020.557710.0000AID71568
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Ki100.00000.00020.640310.0000AID71568
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Ki100.00000.00020.570810.0000AID71568
Gamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)Ki100.00000.00090.89545.6234AID71287
Gamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)Ki100.00000.00020.41199.0000AID71287
Gamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)Ki100.00000.00090.89545.6234AID71287
GABA theta subunitRattus norvegicus (Norway rat)Ki100.00000.00020.656110.0000AID71568
HD2 type histone deacetylase HDA106 Zea maysIC50 (µMol)128.00000.00300.17372.0000AID241474; AID90359
Gamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)Ki100.00000.00090.89545.6234AID71287
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Ki100.00000.00020.656110.0000AID71568
Gamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)Ki100.00000.00090.89545.6234AID71287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (34)

Processvia Protein(s)Taxonomy
chloride transmembrane transportGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
proteolysisLeukotriene A-4 hydrolaseHomo sapiens (human)
lipid metabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
response to zinc ionLeukotriene A-4 hydrolaseHomo sapiens (human)
leukotriene biosynthetic processLeukotriene A-4 hydrolaseHomo sapiens (human)
protein metabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
peptide catabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
response to peptide hormoneLeukotriene A-4 hydrolaseHomo sapiens (human)
type I pneumocyte differentiationLeukotriene A-4 hydrolaseHomo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
monoatomic ion transportGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
response to toxic substanceGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
central nervous system neuron developmentGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
response to progesteroneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
ovulation cycleGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
post-embryonic developmentGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
adult behaviorGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
roof of mouth developmentGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
behavioral fear responseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
associative learningGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
inner ear receptor cell developmentGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
innervationGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
cochlea developmentGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
inner ear receptor cell developmentGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
innervationGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
cochlea developmentGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
negative regulation of chloride transportGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
response to xenobiotic stimulusGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
neurotransmitter transportGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (24)

Processvia Protein(s)Taxonomy
GABA-A receptor activityGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
RNA bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
aminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
epoxide hydrolase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
leukotriene-A4 hydrolase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
protein bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
peptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
zinc ion bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
tripeptide aminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
metalloaminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
GABA receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
ligand-gated monoatomic ion channel activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA receptor bindingGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
identical protein bindingGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
signaling receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA receptor bindingGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA receptor activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA receptor bindingGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
transmembrane signaling receptor activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
neurotransmitter transmembrane transporter activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (35)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
apical plasma membraneGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
axonGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
dendriteGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
neuronal cell bodyGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
extracellular regionLeukotriene A-4 hydrolaseHomo sapiens (human)
nucleoplasmLeukotriene A-4 hydrolaseHomo sapiens (human)
cytosolLeukotriene A-4 hydrolaseHomo sapiens (human)
extracellular exosomeLeukotriene A-4 hydrolaseHomo sapiens (human)
tertiary granule lumenLeukotriene A-4 hydrolaseHomo sapiens (human)
ficolin-1-rich granule lumenLeukotriene A-4 hydrolaseHomo sapiens (human)
cytosolLeukotriene A-4 hydrolaseHomo sapiens (human)
nucleusLeukotriene A-4 hydrolaseHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA receptor complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
nuclear envelopeGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
dendriteGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
presynaptic active zone membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
Schaffer collateral - CA1 synapseGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
axonGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
nucleoplasmGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
cytosolGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
neuronal cell body membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
presynaptic membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
axonGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synaptic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
neuronal cell bodyGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
inhibitory synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
extracellular exosomeGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
postsynaptic membraneGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
cerebellar Golgi cell to granule cell synapseGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
nucleolusGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
microtubule cytoskeletonGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
receptor complexGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (495)

Assay IDTitleYearJournalArticle
AID1193697Therapeutic index, ratio of LD50 for mouse to ED50 for anticonvulsant activity in mouse2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Synthesis, anticonvulsant activity and molecular modeling study of some new hydrazinecarbothioamide, benzenesulfonohydrazide, and phenacylacetohydrazide analogues of 4(3H)-quinazolinone.
AID1292454Half life ( 6 to 24 hrs) in healthy human subjects (6 subjects) at 600 mg, po administered as single enteric-coated compound dose measured by GLC method1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID475798Anticonvulsant activity in ip dosed albino mouse assessed as protection against subcutaneous metrazole-induced seizures2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Lacosamide isothiocyanate-based agents: novel agents to target and identify lacosamide receptors.
AID1292542Unbound serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 8 hrs by enzyme multiple immunotechnique
AID1161067Protective index, ratio of TD50 for neurotoxicity in ip dosed Sprague-Dawley rat to ED50 for anticonvulsant activity in ip dosed MES Sprague-Dawley rat model2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Novel fluorinated pyrrolo[1,2-a]pyrazine-2,6-dione derivatives: synthesis and anticonvulsant evaluation in animal models of epilepsy.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID682350Anticonvulsant activity in mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 300 mg/kg, ip after 0.5 hrs2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis of some novel 1-(2-naphthyl)-2-(imidazol-1-yl)ethanone oxime ester derivatives and evaluation of their anticonvulsant activity.
AID682346Anticonvulsant activity in mouse assessed as protection against maximal electroshock-induced seizures at 100 mg/kg, ip after 4 hrs2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis of some novel 1-(2-naphthyl)-2-(imidazol-1-yl)ethanone oxime ester derivatives and evaluation of their anticonvulsant activity.
AID475797Protective index, ratio of TD50 for po dosed Sprague-Dawley rat to ED50 for protection against maximal electroshock-induced seizures in po dosed Sprague-Dawley rat2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Lacosamide isothiocyanate-based agents: novel agents to target and identify lacosamide receptors.
AID212017Toxicity measured in mouse by subcutaneous administration1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
A novel class of "GABAergic" agents: 1-aryl-3-(aminoalkylidene)oxindoles.
AID1358187Anticonvulsant activity in Swiss albino mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 300 mg/kg, ip administered 0.5 hrs prior to PTZ challenge and measured after 30 mins2018European journal of medicinal chemistry, May-10, Volume: 151Discovery of novel Methylsulfonyl phenyl derivatives as potent human Cyclooxygenase-2 inhibitors with effective anticonvulsant action: Design, synthesis, in-silico, in-vitro and in-vivo evaluation.
AID750675Anticonvulsant activity in albino CF-1 mouse assessed as protection against subcutaneous metrazole-induced seizures in half or more animals at 300 mg/kg, ip after 4 hrs2013European journal of medicinal chemistry, Jun, Volume: 64Augmentation of GABAergic neurotransmission by novel N-(substituted)-2-[4-(substituted)benzylidene]hydrazinecarbothioamides-a potential anticonvulsant approach.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1185524Anticonvulsant activity in ip dosed Kunming mouse assessed as protection against MES-induced seizures after 0.5 hrs by MES test2014European journal of medicinal chemistry, Sep-12, Volume: 84Synthesis and anticonvulsant activity of novel purine derivatives.
AID621654Neurotoxicity in ip dosed albino CF1 mouse assessed as time of peak effect by rotarod test2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Defining the structural parameters that confer anticonvulsant activity by the site-by-site modification of (R)-N'-benzyl 2-amino-3-methylbutanamide.
AID650779Anticonvulsant activity in mouse assessed as protection against maximal electroshock-induced seizure at 1.5 mmol/kg, ip administered 30 min prior to maximal electroshock-challenge measured after 60 mins relative to control2012Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
Design and synthesis of novel 7-aminoquinazoline derivatives: antitumor and anticonvulsant activities.
AID382386Anticonvulsant activity in mouse assessed as inhibition of pentylenetetrazole-induced seizure at 300 mg/kg, ip after 4 hrs2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Synthesis and CNS depressant activity of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones.
AID1292484Tmax in epileptic patient (6 patients) at 800 mg, po administered as single dose by gas liquid chromatographic method1978British journal of clinical pharmacology, Jun, Volume: 5, Issue:6
Disposition of sodium valproate in epileptic patients.
AID638637Anticonvulsant activity in ip dosed albino CF-1 mouse assessed as protection against subcutaneous metrazol-induced seizures after 0.5 hrs2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Design, synthesis and anticonvulsant evaluation of novel N-(4-substituted phenyl)-2-[4-(substituted) benzylidene]-hydrazinecarbothio amides.
AID509489Neurotoxicity in ip dosed albino mouse assessed as inability to maintain equilibrium on rotarod after 30 mins by rotarod test2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
N'-[(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene] 2/4-substituted hydrazides: synthesis and anticonvulsant activity.
AID509491Anticonvulsant activity in ip dosed albino mouse assessed as protection against scPTZ-induced seizures after 0.5 hrs2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Design & synthesis of 2-(substituted aryloxy)-5-(substituted benzylidene)-3-phenyl-2,5-dihydro-1H-[1,2,4] triazin-6-one as potential anticonvulsant agents.
AID765785Teratogenicity in SWV/Fnn mouse assessed as fetuses with neural tube defects at 181 mg/kg, ip on day 8.5 of gestation relative to vehicle-treated control2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID1161069Neurotoxicity in ip dosed Sprague-Dawley rat measured at 0.25 hr post dose2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Novel fluorinated pyrrolo[1,2-a]pyrazine-2,6-dione derivatives: synthesis and anticonvulsant evaluation in animal models of epilepsy.
AID727854Antiepileptic activity in Swiss albino mouse assessed as protection against scPTZ-induced seizures at 300 mg/kg, ip measured after 4 hrs2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Novel limonene and citral based 2,5-disubstituted-1,3,4-oxadiazoles: a natural product coupled approach to semicarbazones for antiepileptic activity.
AID1292533Unbound serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 0.33 hrs by enzyme multiple immunotechnique
AID1292553Fraction unbound in healthy human (6 volunteers) serum at 1 g, po administered as single dose measured after 1.5 hrs
AID1292462Plasma protein binding in healthy human subjects (6 subjects) measured under steady state conditions by equilibrium dialysis method1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID1292527Total serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 12 hrs by gas liquid chromatography
AID682353Anticonvulsant activity in mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 30 mg/kg, ip after 4 hrs2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis of some novel 1-(2-naphthyl)-2-(imidazol-1-yl)ethanone oxime ester derivatives and evaluation of their anticonvulsant activity.
AID1292495Apparent volume of distribution in healthy volunteer (6 volunteers) at 800 mg, iv administered as single dose by gas liquid chromatographic method1978British journal of clinical pharmacology, Jun, Volume: 5, Issue:6
Disposition of sodium valproate in epileptic patients.
AID1292528Total serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 14 hrs by gas liquid chromatography
AID1292562Fraction unbound in healthy human (6 volunteers) serum at 1 g, po administered as single dose measured after 14 hrs
AID443562Protective index, ratio of TD50 for ip dosed albino CF1 mouse to ED50 for ip dosed albino CF1 mouse2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Synthesis and anticonvulsant activities of (R)-N-(4'-substituted)benzyl 2-acetamido-3-methoxypropionamides.
AID569170Neurotoxicity in albino CF-1 mouse assessed as motor impairment at 300 mg/kg, ip after 4 hrs by rotarod test2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Design & synthesis of N'-[substituted] pyridine-4-carbohydrazides as potential anticonvulsant agents.
AID475799Anticonvulsant activity in po dosed Sprague-Dawley rat assessed as protection against subcutaneous metrazole-induced seizures2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Lacosamide isothiocyanate-based agents: novel agents to target and identify lacosamide receptors.
AID395122Anticonvulsant activity in mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures at 80 mg/kg, po2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Synthesis and potential anticonvulsant activity of new N-3-substituted 5,5-cyclopropanespirohydantoins.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1574758Anticonvulsant activity in amygdala kindling rat model assessed as change in after discharge threshold at 600 mg/kg, po relative to control2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
Identification of 2-(2'-fluoro-[1,1'-biphenyl]-2-yl)acetamide as a Sodium Valproate-like broad spectrum anti-epileptic drug candidate.
AID650780Protective index, ratio of TD50 for mouse to ED50 for pentylenetetrazol-induced seizure in mouse2012Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
Design and synthesis of novel 7-aminoquinazoline derivatives: antitumor and anticonvulsant activities.
AID1175002Neurotoxicity in ip dosed Swiss CF1 mouse assessed as induction of motor impairment measured after 4 hrs by rotorod test2014Bioorganic & medicinal chemistry letters, Dec-15, Volume: 24, Issue:24
Microwave assisted synthesis and docking study of N-(2-oxo-2-(4-oxo-2-substituted thiazolidin-3ylamino)ethyl)benzamide derivatives as anticonvulsant agents.
AID727848Neurotoxicity against Swiss albino mouse by rotarod test at 300 mg/kg, ip after 4 hrs2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Novel limonene and citral based 2,5-disubstituted-1,3,4-oxadiazoles: a natural product coupled approach to semicarbazones for antiepileptic activity.
AID621650Anticonvulsant activity in po dosed albino Sprague-Dawley rat assessed as time of peak effect by maximal electroshock seizures test in presence of 150 miliamperes of electric current2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Defining the structural parameters that confer anticonvulsant activity by the site-by-site modification of (R)-N'-benzyl 2-amino-3-methylbutanamide.
AID608519Anticonvulsant activity against maximal electric shock-induced seizures in ip dosed Kunming mouse assessed as median effective dose2011European journal of medicinal chemistry, Jul, Volume: 46, Issue:7
Synthesis and anticonvulsant activity of 7-phenyl-6,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidin-5(4H)-ones and their derivatives.
AID1292456AUC in healthy human subjects (6 subjects) at 600 mg, po administered as single enteric-coated compound dose measured by GLC method1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID443560Anticonvulsant activity in ip dosed albino CF1 mouse seizure model assessed as protection against hind limb extension by MES test2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Synthesis and anticonvulsant activities of (R)-N-(4'-substituted)benzyl 2-acetamido-3-methoxypropionamides.
AID1292558Fraction unbound in healthy human (6 volunteers) serum at 1 g, po administered as single dose measured after 6 hrs
AID682319Neurotoxicity in mouse assessed as motor impairment at 100 mg/kg, ip after 4 hrs by rotarod test2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis of some novel 1-(2-naphthyl)-2-(imidazol-1-yl)ethanone oxime ester derivatives and evaluation of their anticonvulsant activity.
AID1292526Total serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 10 hrs by gas liquid chromatography
AID625826Anticonvulsant activity in ip dosed Swiss albino CF1 mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures after 0.5 hrs2011European journal of medicinal chemistry, Nov, Volume: 46, Issue:11
Design and synthesis of 2-(1, 3-dioxoisoindolin-2-yl)-N-(4-oxo-2-substitutedthiazolidin-3-yl) acetamide derivatives as potential anticonvulsant agents.
AID114802Anticonvulsant activity in tonic seizures when administered orally in mice1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and activity of 6-aryl-3-(hydroxypolymethyleneamino)pyridazines in animal models of epilepsy.
AID443568Anticonvulsant activity against subcutaneous metrazole-induced seizures in albino Sprague-Dawley rat at 300 mg/kg, ip after 0.5 hrs2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Synthesis and anticonvulsant activities of (R)-N-(4'-substituted)benzyl 2-acetamido-3-methoxypropionamides.
AID750671Neurotoxicity in ip dosed albino CF-1 mouse assessed as minimal motor impairment in half or more animals after 4 hrs by rotarod test2013European journal of medicinal chemistry, Jun, Volume: 64Augmentation of GABAergic neurotransmission by novel N-(substituted)-2-[4-(substituted)benzylidene]hydrazinecarbothioamides-a potential anticonvulsant approach.
AID1292476Half life in epileptic patient (6 patients) at 800 mg, iv administered as single dose by gas liquid chromatographic method1978British journal of clinical pharmacology, Jun, Volume: 5, Issue:6
Disposition of sodium valproate in epileptic patients.
AID1489012Anticonvulsant activity in amygdala kindling rat model assessed as change in after discharge duration at 600 mg/kg, po (Rvb = -5.5%)2017Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
N-alkyl-[1,1'-biphenyl]-2-sulfonamide derivatives as novel broad spectrum anti-epileptic drugs with efficacy equivalent to that of sodium valproate.
AID1292539Unbound serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 4 hrs by enzyme multiple immunotechnique
AID637073Anticonvulsant activity in ip dosed Kunming mouse assessed as protection against maximal electroshock-induced seizure2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and anticonvulsant activity of 1-(8-(benzyloxy)quinolin-2-yl)-6-substituted-4,6-diazaspiro[2,4]heptane-5,7-diones.
AID682344Anticonvulsant activity in mouse assessed as protection against maximal electroshock-induced seizures at 300 mg/kg, ip after 0.5 hrs2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis of some novel 1-(2-naphthyl)-2-(imidazol-1-yl)ethanone oxime ester derivatives and evaluation of their anticonvulsant activity.
AID489289Neurotoxicity in Swiss albino mouse at 300 mg/kg, ip after 4 hrs2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Novel semicarbazones based 2,5-disubstituted-1,3,4-oxadiazoles: one more step towards establishing four binding site pharmacophoric model hypothesis for anticonvulsant activity.
AID682349Anticonvulsant activity in mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 100 mg/kg, ip after 0.5 hrs2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis of some novel 1-(2-naphthyl)-2-(imidazol-1-yl)ethanone oxime ester derivatives and evaluation of their anticonvulsant activity.
AID1292481AUC (0 to infinity) in epileptic patient (6 patients) at 800 mg, iv administered as single dose by gas liquid chromatographic method1978British journal of clinical pharmacology, Jun, Volume: 5, Issue:6
Disposition of sodium valproate in epileptic patients.
AID480301Protective index, ratio of TD50 for Sprague-Dawley albino rat to anticonvulsant ED50 for Sprague-Dawley albino rat2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities.
AID1441699Inhibition of recombinant human LTA4H aminopeptidase activity expressed in Escherichia coli BL21 (DE3) pLysS assessed as formation of p-NA from Ala-p-NA at 10 uM preincubated for 10 mins followed by substrate addition measured after 10 mins2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID727986Antiepileptic activity in Swiss albino mouse assessed as protection against maximal-electric shock-induced seizures at 300 mg/kg, ip measured after 4 hrs2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Novel limonene and citral based 2,5-disubstituted-1,3,4-oxadiazoles: a natural product coupled approach to semicarbazones for antiepileptic activity.
AID638717Neurotoxicity in albino CF-1 mouse assessed as minimum motor impairment at 300 mg/kg, ip after 4 hrs by rotarod test2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Design, synthesis and anticonvulsant evaluation of novel N-(4-substituted phenyl)-2-[4-(substituted) benzylidene]-hydrazinecarbothio amides.
AID1074413Anticonvulsant activity in KunMing mouse assessed as protection against maximal electroshock-induced seizures at 300 mg/kg, ip after 4 hrs2014European journal of medicinal chemistry, Feb-12, Volume: 73Design, synthesis and evaluation of the antidepressant and anticonvulsant activities of triazole-containing quinolinones.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1441630Inhibition of recombinant human LTA4H aminopeptidase activity expressed in Escherichia coli BL21 (DE3) pLysS assessed as formation of p-NA from Ala-p-NA preincubated for 10 mins followed by substrate addition measured after 10 mins2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID727849Neurotoxicity against Swiss albino mouse by rotarod test at 300 mg/kg, ip after 0.5 hrs2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Novel limonene and citral based 2,5-disubstituted-1,3,4-oxadiazoles: a natural product coupled approach to semicarbazones for antiepileptic activity.
AID1292491Ratio of AUC (0 to infinity) in epileptic patient (6 patients) at 800 mg, po administered as single dose to AUC (0 to infinity) in epileptic patient (6 patients) at 800 mg, iv administered as single dose1978British journal of clinical pharmacology, Jun, Volume: 5, Issue:6
Disposition of sodium valproate in epileptic patients.
AID638634Anticonvulsant activity in albino CF-1 mouse assessed as protection against maximal electroshock-induced seizures at 300 mg/kg, ip after 2 hrs2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Design, synthesis and anticonvulsant evaluation of novel N-(4-substituted phenyl)-2-[4-(substituted) benzylidene]-hydrazinecarbothio amides.
AID545526Protective index, ratio of TD50 for mouse to ED50 for inhibition of subcutaneous pentylenetetrazole-induced seizure in mouse2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Synthesis and anticonvulsant activity of N-3-arylamide substituted 5,5-cyclopropanespirohydantoin derivatives.
AID682348Anticonvulsant activity in mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 30 mg/kg, ip after 0.5 hrs2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis of some novel 1-(2-naphthyl)-2-(imidazol-1-yl)ethanone oxime ester derivatives and evaluation of their anticonvulsant activity.
AID489277Anticonvulsant activity against subcutaneous strychnine-induced seizures in Wistar rat at 300 mg/kg, ip after 4 hrs2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Novel semicarbazones based 2,5-disubstituted-1,3,4-oxadiazoles: one more step towards establishing four binding site pharmacophoric model hypothesis for anticonvulsant activity.
AID1292554Fraction unbound in healthy human (6 volunteers) serum at 1 g, po administered as single dose measured after 2 hrs
AID1563904Anticonvulsive activity in albino mouse assessed as protection against pentylenetetrazole-induced seizure by measuring severity of convulsion at 300 mg/kg, ig administered 30 mins prior to pentylenetetrazole challenge and mesured for 60 mins (Rvb = 5.83 +2019European journal of medicinal chemistry, Oct-15, Volume: 180Synthesis, in vivo and in silico anticonvulsant activity studies of new derivatives of 2-(2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)acetamide.
AID1292499Oral bioavailability in epileptic patient (6 patients) at 800 mg administered as single dose by gas liquid chromatographic method1978British journal of clinical pharmacology, Jun, Volume: 5, Issue:6
Disposition of sodium valproate in epileptic patients.
AID551906Anticonvulsant activity against PTZ-induced kindling Wistar rat model assessed as duration of behavirol seizure at 100 mg/kg, ip2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Imidazolylchromanone oxime ethers as potential anticonvulsant agents: Anticonvulsive evaluation in PTZ-kindling model of epilepsy and SAR study.
AID364289Anticonvulsant activity in mouse at 300 mg/kg, ip after 4 hrs by MES test2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
CNS depressant and anticonvulsant activities of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones.
AID1489023Anticonvulsant activity in po dosed subcutaneous pentylenetetrazole-induced seizure mouse model assessed as reduction in convulsions2017Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
N-alkyl-[1,1'-biphenyl]-2-sulfonamide derivatives as novel broad spectrum anti-epileptic drugs with efficacy equivalent to that of sodium valproate.
AID637075Protective index, ratio of TD50 for ip dosed Kunming mouse to ED50 for ip dosed Kunming mouse by maximal electroshock seizure test2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and anticonvulsant activity of 1-(8-(benzyloxy)quinolin-2-yl)-6-substituted-4,6-diazaspiro[2,4]heptane-5,7-diones.
AID241474Inhibitory concentration against maize histone deacetylase 22005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides.
AID509493Anticonvulsant activity in ip dosed albino mouse assessed as protection against MES-induced seizures after 0.5 hrs2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Design & synthesis of 2-(substituted aryloxy)-5-(substituted benzylidene)-3-phenyl-2,5-dihydro-1H-[1,2,4] triazin-6-one as potential anticonvulsant agents.
AID693327Protective index, ratio of TD50 for mouse to ED50 for anticonvulsant activity in mouse by subcutaneous pentylenetetrazol-induced seizure test2012European journal of medicinal chemistry, Dec, Volume: 58Design, synthesis and evaluation of N-(substituted benzothiazol-2-yl)amides as anticonvulsant and neuroprotective.
AID443570Anticonvulsant activity against subcutaneous metrazole-induced seizures in albino Sprague-Dawley rat at 300 mg/kg, ip after 4 hrs2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Synthesis and anticonvulsant activities of (R)-N-(4'-substituted)benzyl 2-acetamido-3-methoxypropionamides.
AID114126Anticonvulsant activity in mice using the maximal electroshock seizure test.1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Synthesis and anticonvulsant properties of new benzylpyridazine derivatives.
AID1185526Protective index, ratio of intraperitoneal neurotoxic TD50 against Kunming mouse by rotarod test to intraperitoneal anticonvulsant ED50 in Kunming mouse by MES test2014European journal of medicinal chemistry, Sep-12, Volume: 84Synthesis and anticonvulsant activity of novel purine derivatives.
AID621653Behavioral toxicity in po dosed albino Sprague-Dawley rat assessed as time of peak effect2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Defining the structural parameters that confer anticonvulsant activity by the site-by-site modification of (R)-N'-benzyl 2-amino-3-methylbutanamide.
AID619697Anticonvulsant activity in po dosed albino Sprague-Dawley rat assessed as protection against maximal electroshock seizure2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Primary amino acid derivatives: substitution of the 4'-N'-benzylamide site in (R)-N'-benzyl 2-amino-3-methylbutanamide, (R)-N'-benzyl 2-amino-3,3-dimethylbutanamide, and (R)-N'-benzyl 2-amino-3-methoxypropionamide provides potent anticonvulsants with pain
AID1563903Anticonvulsive activity in pentylenetetrazole-induced seizure albino mouse model assessed as proportion of animals with tonic convulsion at 300 mg/kg, ig administered 30 mins prior to pentylenetetrazole challenge and mesured for 60 mins (Rvb = 100%)2019European journal of medicinal chemistry, Oct-15, Volume: 180Synthesis, in vivo and in silico anticonvulsant activity studies of new derivatives of 2-(2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)acetamide.
AID364304Neurotoxicity in mouse assessed as minimal motor impairment at 300 mg/kg, ip after 0.5 hrs by rotarod test2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
CNS depressant and anticonvulsant activities of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones.
AID621652Protective index, ratio of TD50 for albino Sprague-Dawley rat to ED50 for albino Sprague-Dawley rat by maximal electroshock seizures test2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Defining the structural parameters that confer anticonvulsant activity by the site-by-site modification of (R)-N'-benzyl 2-amino-3-methylbutanamide.
AID366629Protective index, ratio of TD50 for mouse by rotarod test to ED50 for mouse by scMET test2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Anticonvulsant activity of some xanthone derivatives.
AID112398Yohimbine induced seizures by administrating sc and the compound which do not exhibit at least one clonic seizure within 60 min was recorded; Percentage of protection at 150 mg/kg per os.1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Synthesis and anticonvulsant properties of new benzylpyridazine derivatives.
AID1292564Fraction unbound in healthy human (6 volunteers) serum at 1 g, po administered as single dose measured after 30 hrs
AID688819Toxicity in Swiss albino mouse assessed as mortality at 1.38 mmol/kg, sc2011European journal of medicinal chemistry, Nov, Volume: 46, Issue:11
Synthesis and anticonvulsant activity of some new thiazolo[3,2-a][1,3]diazepine, benzo[d]thiazolo[5,2-a][12,6]diazepine and benzo[d]oxazolo[5,2-a][12,6]diazepine analogues.
AID387785Neurotoxicity in ip dosed albino mouse by rotarod test2008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Synthesis and anticonvulsant activities of N-benzyl (2R)-2-acetamido-3-oxysubstituted propionamide derivatives.
AID1292460Steady state plasma concentration before morning dose in healthy human subjects (6 subjects) at 1200 mg, po for 12 days administered as enteric-coated compound dose by GLC method1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID112309Effective dose which decreases the 50% of the convulsions induced by bicuculline in mice1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
New anticonvulsants: Schiff bases of gamma-aminobutyric acid and gamma-aminobutyramide.
AID128132Ability to inhibit seizures induced by electroshock in mice administered per orally1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis and anticonvulsant and sedative-hypnotic activity of 4-(alkylimino)-2,3-dihydro-4H-1-benzopyrans and -benzothiopyrans.
AID551908Anticonvulsant activity against PTZ-induced kindling Wistar rat model assessed as duration of behavirol seizure at 200 mg/kg, ip2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Imidazolylchromanone oxime ethers as potential anticonvulsant agents: Anticonvulsive evaluation in PTZ-kindling model of epilepsy and SAR study.
AID1720865Protective index, ratio of TD50 for neurotoxicity in ip injected albino mouse to ED50 for anticonvulsant activity in albino mouse assessed as pentylenetetrazole-induced seizure2020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Synthetic and therapeutic perspectives of nitrogen containing heterocycles as anti-convulsants.
AID112310Effective dose which decreases the 50% of the lethality induced by bicuculline in mice1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
New anticonvulsants: Schiff bases of gamma-aminobutyric acid and gamma-aminobutyramide.
AID727993Antiepileptic activity in ip dosed Swiss albino mouse assessed as protection against maximal-electric shock-induced seizures after 0.5 hrs2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Novel limonene and citral based 2,5-disubstituted-1,3,4-oxadiazoles: a natural product coupled approach to semicarbazones for antiepileptic activity.
AID489281Anticonvulsant activity against subcutaneous pentylenetetrazole-induced seizures in Swiss albino mouse at 300 mg/kg, ip after 4 hrs2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Novel semicarbazones based 2,5-disubstituted-1,3,4-oxadiazoles: one more step towards establishing four binding site pharmacophoric model hypothesis for anticonvulsant activity.
AID625737Neurotoxicity in Swiss albino CF1 mouse assessed as minimal motor deficit at 30 to 300 mg/kg, ip after 0.5 hrs by rotarod test2011European journal of medicinal chemistry, Nov, Volume: 46, Issue:11
Design and synthesis of 2-(1, 3-dioxoisoindolin-2-yl)-N-(4-oxo-2-substitutedthiazolidin-3-yl) acetamide derivatives as potential anticonvulsant agents.
AID1489026Anticonvulsant activity in po dosed maximal electroshock induced seizure mouse model assessed as reduction in convulsions2017Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
N-alkyl-[1,1'-biphenyl]-2-sulfonamide derivatives as novel broad spectrum anti-epileptic drugs with efficacy equivalent to that of sodium valproate.
AID619783Toxicity in po dosed albino Sprague-Dawley rat assessed as time of peak effect for behavioural toxicity2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Primary amino acid derivatives: substitution of the 4'-N'-benzylamide site in (R)-N'-benzyl 2-amino-3-methylbutanamide, (R)-N'-benzyl 2-amino-3,3-dimethylbutanamide, and (R)-N'-benzyl 2-amino-3-methoxypropionamide provides potent anticonvulsants with pain
AID650788Anticonvulsant activity in mouse assessed as protection against picrotoxin-induced seizure at 1.5 mmol/kg, ip administered 30 min prior to picrotoxin-challenge measured after 60 mins relative to control2012Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
Design and synthesis of novel 7-aminoquinazoline derivatives: antitumor and anticonvulsant activities.
AID477356Neurotoxicity in ip dosed Swiss albino mouse2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
Triazole incorporated thiazoles as a new class of anticonvulsants: design, synthesis and in vivo screening.
AID114576Tested for the abolition of the hand leg tonic extensor component of the seizure induced by a 0.96 mg/kg sc injection of strychnine; Percentage of protection at 100 mg/kg per os.1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Synthesis and anticonvulsant properties of new benzylpyridazine derivatives.
AID1574765Anticonvulsant activity in po dosed 6-Hz induced seizure mouse model2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
Identification of 2-(2'-fluoro-[1,1'-biphenyl]-2-yl)acetamide as a Sodium Valproate-like broad spectrum anti-epileptic drug candidate.
AID639296Neurotoxicity in ip dosed Swiss albino mouse assessed as mortality2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Synthesis and anticonvulsant evaluation of some new 2,3,8-trisubstituted-4(3H)-quinazoline derivatives.
AID1292470Drug excretion in urine of healthy human subjects (6 subjects) assessed as valproic acid level at 1200 mg, po for 12 days administered as enteric-coated compound dose measured during 24 hrs relative to total drug excretion1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID128181Compound was tested for enhancement of [3H]Flunitrazepam ([3H]FNP) binding to mouse brain after intraperitoneal administration at a dose of 1000uM/kg, expressed as percent of control1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
A novel class of "GABAergic" agents: 1-aryl-3-(aminoalkylidene)oxindoles.
AID480279Anticonvulsant activity in ip dosed albino mouse assessed as inhibition of maximal electroshock-induced seizures after 0.25 hrs2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities.
AID1441631Inhibition of recombinant human LTA4H Epoxide Hydrolase expressed in Escherichia coli BL21 (DE3) pLysS preincubated for 10 mins followed by addition of LTA4 as substrate measured after 15 mins by reverse-phase HPLC analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1292455Terminal half life in healthy human subjects (6 subjects) at 600 mg, po administered as single enteric-coated compound dose measured by GLC method1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1292523Total serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 5 hrs by gas liquid chromatography
AID1574757Anticonvulsant activity in amygdala kindling rat model assessed as change in after discharge threshold at 300 mg/kg, po relative to control2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
Identification of 2-(2'-fluoro-[1,1'-biphenyl]-2-yl)acetamide as a Sodium Valproate-like broad spectrum anti-epileptic drug candidate.
AID34964Inhibitory activity measured against rat lens aldose reductase using 3-pyridinecarboxaldehyde as substrate1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
A highly specific aldose reductase inhibitor, ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate, and its congeners.
AID1161079Anticonvulsant activity in ip dosed corneal kindled albino CF1 mouse seizure model assessed as time to peak effect2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Novel fluorinated pyrrolo[1,2-a]pyrazine-2,6-dione derivatives: synthesis and anticonvulsant evaluation in animal models of epilepsy.
AID1655739Cytotoxicity against human M221 cells assessed as reduction in cell viability at 50 to 800 nM measured after 72 hrs by Celltiter-Glo luminescent assay2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
Predictive Gene Signature for Pyrazolopyrimidine Derivative c-Src Inhibitor 10a Sensitivity in Melanoma Cells.
AID71568Displacement of [3H]gamma-amino butyric acid from Gamma-aminobutyric acid (GABA-A) receptor of rat ganglion neurons1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
New anticonvulsants: Schiff bases of gamma-aminobutyric acid and gamma-aminobutyramide.
AID1292477Extrapolated volume of distribution in epileptic patient (6 patients) at 800 mg, iv administered as single dose by gas liquid chromatographic method1978British journal of clinical pharmacology, Jun, Volume: 5, Issue:6
Disposition of sodium valproate in epileptic patients.
AID114634Anticonvulsant activity in Maximal electroshock (MES) when administered orally in mice1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and activity of 6-aryl-3-(hydroxypolymethyleneamino)pyridazines in animal models of epilepsy.
AID1292468Ratio of urinary excretion of valproic acid to urinary excretion of VPA-conjugates in healthy human subjects (6 subjects) at 600 mg, po administered as single enteric-coated compound1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID1292551Fraction unbound in healthy human (6 volunteers) serum at 1 g, po administered as single dose measured after 0.66 hrs
AID1292547Unbound serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 30 hrs by enzyme multiple immunotechnique
AID1292567Tmax in healthy human (6 volunteers) at 1 g, po administered as single dose by gas liquid chromatography
AID765782Teratogenicity in SWV/Fnn mouse assessed as normal fetuses at 301 mg/kg, ip on day 8.5 of gestation (Rvb = 100 %)2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID1292485Elimination rate constant in epileptic patient (6 patients) at 800 mg, po administered as single dose by gas liquid chromatographic method1978British journal of clinical pharmacology, Jun, Volume: 5, Issue:6
Disposition of sodium valproate in epileptic patients.
AID489284Anticonvulsant activity against subcutaneous pentylenetetrazole-induced seizures in ip dosed Swiss albino mouse assessed as minimum effective dose after 0.5 hrs2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Novel semicarbazones based 2,5-disubstituted-1,3,4-oxadiazoles: one more step towards establishing four binding site pharmacophoric model hypothesis for anticonvulsant activity.
AID1441632Binding affinity to recombinant human LTA4H hydrolase assessed as change in melting temperature at 50 uM by SYPRO orange dye-based thermofluor assay2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID443569Anticonvulsant activity against subcutaneous metrazole-induced seizures in albino CF1 mouse at 300 mg/kg, ip after 4 hrs2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Synthesis and anticonvulsant activities of (R)-N-(4'-substituted)benzyl 2-acetamido-3-methoxypropionamides.
AID212013Toxicity was measured in mouse by intraperitoneal administration1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
A novel class of "GABAergic" agents: 1-aryl-3-(aminoalkylidene)oxindoles.
AID540235Phospholipidosis-negative literature compound
AID1292538Unbound serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 3 hrs by enzyme multiple immunotechnique
AID1563907Anticonvulsive activity in pentylenetetrazole-induced seizure albino mouse model assessed as lethality at 300 mg/kg, ig administered 30 mins prior to pentylenetetrazole challenge and mesured for 60 mins (Rvb = 91.7%)2019European journal of medicinal chemistry, Oct-15, Volume: 180Synthesis, in vivo and in silico anticonvulsant activity studies of new derivatives of 2-(2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)acetamide.
AID480302Anticonvulsant activity in albino mouse assessed as protection against subcutaneous metrazole-induced seizures up to 300 mg/kg, ip after 0.5 hrs2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities.
AID619695Neurotoxicity in ip dosed albino CF1 mouse assessed as median neurological impairing dose after 30 mins2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Primary amino acid derivatives: substitution of the 4'-N'-benzylamide site in (R)-N'-benzyl 2-amino-3-methylbutanamide, (R)-N'-benzyl 2-amino-3,3-dimethylbutanamide, and (R)-N'-benzyl 2-amino-3-methoxypropionamide provides potent anticonvulsants with pain
AID1143177Anticonvulsant activity in Swiss albino mouse assessed as protection against PTZ-induced seizure at 200 mg/kg, po administered 60 mins prior to pentylenetetrazole challenge2014European journal of medicinal chemistry, Jun-10, Volume: 80Anticonvulsant evaluation of clubbed indole-1,2,4-triazine derivatives: a synthetic approach.
AID638636Anticonvulsant activity in albino CF-1 mouse assessed as protection against maximal electroshock-induced seizures at 300 mg/kg, ip after 4 hrs2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Design, synthesis and anticonvulsant evaluation of novel N-(4-substituted phenyl)-2-[4-(substituted) benzylidene]-hydrazinecarbothio amides.
AID113457Anticonvulsant activity against bicuculline induced seizures in mice; Percentage of protection at 100 mg/kg per os.1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Synthesis and anticonvulsant properties of new benzylpyridazine derivatives.
AID621651Neurotoxicity in po dosed albino Sprague-Dawley rat2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Defining the structural parameters that confer anticonvulsant activity by the site-by-site modification of (R)-N'-benzyl 2-amino-3-methylbutanamide.
AID551907Anticonvulsant activity against PTZ-induced kindling Wistar rat model assessed as seizure latency at 200 mg/kg, ip2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Imidazolylchromanone oxime ethers as potential anticonvulsant agents: Anticonvulsive evaluation in PTZ-kindling model of epilepsy and SAR study.
AID608517Protective index, ratio of TD50 for neurotoxicity in Kunming mouse to ED50 for inhibition of MES-induced seizures in Kunming mouse2011European journal of medicinal chemistry, Jul, Volume: 46, Issue:7
Synthesis and anticonvulsant activity of 7-phenyl-6,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidin-5(4H)-ones and their derivatives.
AID480299Behavioral toxicity in po dosed Sprague-Dawley albino rat after 0.5 hrs2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities.
AID1292544Unbound serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 12 hrs by enzyme multiple immunotechnique
AID475794Neurotoxicity in po dosed Sprague-Dawley rat by rotarod test2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Lacosamide isothiocyanate-based agents: novel agents to target and identify lacosamide receptors.
AID475793Anticonvulsant activity against maximal electroshock-induced seizures in po dosed Sprague-Dawley rat assessed as time of peak effect2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Lacosamide isothiocyanate-based agents: novel agents to target and identify lacosamide receptors.
AID639294Anticonvulsant activity in ip dosed Swiss albino mouse assessed as protection against PTZ-induced seizure compound administered 30 mins before challenge measured after 60 mins2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Synthesis and anticonvulsant evaluation of some new 2,3,8-trisubstituted-4(3H)-quinazoline derivatives.
AID1174999Anticonvulsant activity in ip dosed Swiss CF1 mouse measured after 0.5 hrs by scPTZ test2014Bioorganic & medicinal chemistry letters, Dec-15, Volume: 24, Issue:24
Microwave assisted synthesis and docking study of N-(2-oxo-2-(4-oxo-2-substituted thiazolidin-3ylamino)ethyl)benzamide derivatives as anticonvulsant agents.
AID509490Neurotoxicity in ip dosed albino mouse assessed as inability to maintain equilibrium on rotarod after 4 hrs by rotarod test2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
N'-[(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene] 2/4-substituted hydrazides: synthesis and anticonvulsant activity.
AID619778Anticonvulsant activity in ip dosed albino CF1 mouse assessed as time of peak effect for protection against maximal electroshock-induced seizure2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Primary amino acid derivatives: substitution of the 4'-N'-benzylamide site in (R)-N'-benzyl 2-amino-3-methylbutanamide, (R)-N'-benzyl 2-amino-3,3-dimethylbutanamide, and (R)-N'-benzyl 2-amino-3-methoxypropionamide provides potent anticonvulsants with pain
AID449305Anticonvulsant activity in ip dosed albino mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizure after 0.5 hrs2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, anticonvulsant and CNS depressant activity of some new bioactive 1-(4-substituted-phenyl)-3-(4-oxo-2-phenyl/ethyl-4H-quinazolin-3-yl)-urea.
AID1292469Drug excretion in urine of healthy human subjects (6 subjects) assessed as VPA-conjugates level at 1200 mg, po for 12 days administered as enteric-coated compound dose measured during 24 hrs relative to total drug excretion1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID1574768Therapeutic index, ratio of TD50 for neurotoxicity in po dosed mouse to ED50 for po dosed 6-Hz induced seizure mouse model2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
Identification of 2-(2'-fluoro-[1,1'-biphenyl]-2-yl)acetamide as a Sodium Valproate-like broad spectrum anti-epileptic drug candidate.
AID1489010Neurotoxicity in po dosed mouse by rotarod test2017Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
N-alkyl-[1,1'-biphenyl]-2-sulfonamide derivatives as novel broad spectrum anti-epileptic drugs with efficacy equivalent to that of sodium valproate.
AID727991Antiepileptic activity in ip dosed Swiss albino mouse assessed as protection against scPTZ-induced seizures after 0.5 hrs2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Novel limonene and citral based 2,5-disubstituted-1,3,4-oxadiazoles: a natural product coupled approach to semicarbazones for antiepileptic activity.
AID1292500Toxicity in epileptic patient (6 patients) at 800 mg, po and iv administered as single dose by gas liquid chromatographic method1978British journal of clinical pharmacology, Jun, Volume: 5, Issue:6
Disposition of sodium valproate in epileptic patients.
AID1720863Neurotoxicity in ip injected albino mouse2020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Synthetic and therapeutic perspectives of nitrogen containing heterocycles as anti-convulsants.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID750678Anticonvulsant activity in albino CF-1 mouse at 300 mg/kg, ip assessed as protection against maximal electroshock-induced seizures in half or more animals after 2 hrs2013European journal of medicinal chemistry, Jun, Volume: 64Augmentation of GABAergic neurotransmission by novel N-(substituted)-2-[4-(substituted)benzylidene]hydrazinecarbothioamides-a potential anticonvulsant approach.
AID1292531Total serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 39 hrs by gas liquid chromatography
AID1074420Anticonvulsant activity in ip dosed KunMing mouse assessed as protection against maximal electroshock-induced seizures after 0.5 hrs2014European journal of medicinal chemistry, Feb-12, Volume: 73Design, synthesis and evaluation of the antidepressant and anticonvulsant activities of triazole-containing quinolinones.
AID1563902Anticonvulsive activity in pentylenetetrazole-induced seizure albino mouse model assessed as proportion of animals with clonic convulsion at 300 mg/kg, ig administered 30 mins prior to pentylenetetrazole challenge and mesured for 60 mins (Rvb = 100 %)2019European journal of medicinal chemistry, Oct-15, Volume: 180Synthesis, in vivo and in silico anticonvulsant activity studies of new derivatives of 2-(2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)acetamide.
AID551905Anticonvulsant activity against PTZ-induced kindling Wistar rat model assessed as seizure latency at 100 mg/kg, ip2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Imidazolylchromanone oxime ethers as potential anticonvulsant agents: Anticonvulsive evaluation in PTZ-kindling model of epilepsy and SAR study.
AID1292546Unbound serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 24 hrs by enzyme multiple immunotechnique
AID1292441Plasma concentration in healthy human subjects (6 subjects) at 600 mg, po administered as single enteric-coated compound dose measured after 1 hr by GLC method1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID688842Anticonvulsant activity in Swiss albino mouse assessed as protection against pentylenetetrazole-induced convulsion at 1.38 mmol/kg, ip treated after 30 mins of pentylenetetrazole measured for 30 mins2011European journal of medicinal chemistry, Nov, Volume: 46, Issue:11
Synthesis and anticonvulsant activity of some new thiazolo[3,2-a][1,3]diazepine, benzo[d]thiazolo[5,2-a][12,6]diazepine and benzo[d]oxazolo[5,2-a][12,6]diazepine analogues.
AID1292560Fraction unbound in healthy human (6 volunteers) serum at 1 g, po administered as single dose measured after 10 hrs
AID1563918Toxicity in albino mouse assessed as motor coordination impairment by measuring animal fall-off from rod before 3 mins at 300 mg/kg, ig administered 30 mins prior to test by rotarod test (Rvb = 33%)2019European journal of medicinal chemistry, Oct-15, Volume: 180Synthesis, in vivo and in silico anticonvulsant activity studies of new derivatives of 2-(2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)acetamide.
AID366585Anticonvulsant activity against maximal electroshock-induced seizures in ip dosed mouse2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Anticonvulsant activity of some xanthone derivatives.
AID1292519Total serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 1.5 hrs by gas liquid chromatography
AID1292471Ratio of urinary excretion of valproic acid to urinary excretion of VPA-conjugates in healthy human subjects (6 subjects) at at 1200 mg, po for 12 days administered as enteric-coated compound dose measured during 24 hrs relative to total drug excretion1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID1720860Anticonvulsant activity in albino mouse assessed as pentylenetetrazole-induced seizure measured after 30 mins2020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Synthetic and therapeutic perspectives of nitrogen containing heterocycles as anti-convulsants.
AID1292571Total AUC in healthy human (6 volunteers) at 1 g, po administered as single dose by gas liquid chromatography
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID74546Compound was tested for activation of Glutamate decarboxylase which is the ratio of Vmax in the presence of activators to the Vmax in the absence of activators at a concentration of 500 uM.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
3-Alkyl-4-aminobutyric acids: the first class of anticonvulsant agents that activates L-glutamic acid decarboxylase.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID639295Neurotoxicity in ip dosed Swiss albino mouse measured after 30 mins by chimney test2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Synthesis and anticonvulsant evaluation of some new 2,3,8-trisubstituted-4(3H)-quinazoline derivatives.
AID1193696Toxicity in ip dosed mouse assessed as dose required to cause lethality administered 20 mins prior to PTZ challenge relative to control2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Synthesis, anticonvulsant activity and molecular modeling study of some new hydrazinecarbothioamide, benzenesulfonohydrazide, and phenacylacetohydrazide analogues of 4(3H)-quinazolinone.
AID1292492Elimination rate constant in healthy volunteer (6 volunteers) at 800 mg, iv administered as single dose by gas liquid chromatographic method1978British journal of clinical pharmacology, Jun, Volume: 5, Issue:6
Disposition of sodium valproate in epileptic patients.
AID509488Anticonvulsant activity in ip dosed albino mouse assessed as protection against scPTZ-induced seizures after 4 hrs2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
N'-[(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene] 2/4-substituted hydrazides: synthesis and anticonvulsant activity.
AID665943Neurotoxicity in ip dosed NMRI mouse after 30 mins by rotorod test2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Synthesis, anticonvulsant activity, and neuropathic pain-attenuating activity of N-benzyl 2-amino-2-(hetero)aromatic acetamides.
AID621623Anticonvulsant activity in ip dosed albino CF1 mouse assessed as time of peak effect by maximal electroshock seizures test in presence of 50 miliamperes of electric current2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Defining the structural parameters that confer anticonvulsant activity by the site-by-site modification of (R)-N'-benzyl 2-amino-3-methylbutanamide.
AID1489014Anticonvulsant activity in amygdala kindling rat model assessed as change in after discharge duration at 300 mg/kg, po (Rvb = -5.5%)2017Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
N-alkyl-[1,1'-biphenyl]-2-sulfonamide derivatives as novel broad spectrum anti-epileptic drugs with efficacy equivalent to that of sodium valproate.
AID569167Anticonvulsant activity in albino CF-1 mouse assessed as protection against subcutaneous metrazol-induced seizures at 300 mg/kg, ip after 4 hrs2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Design & synthesis of N'-[substituted] pyridine-4-carbohydrazides as potential anticonvulsant agents.
AID1292442Plasma concentration in healthy human subjects (6 subjects) at 600 mg, po administered as single enteric-coated compound dose measured after 2 hrs by GLC method1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID1292555Fraction unbound in healthy human (6 volunteers) serum at 1 g, po administered as single dose measured after 3 hrs
AID621625Protective index, ratio of TD50 for albino CF1 mouse by rotarod test to ED50 for albino CF1 mouse by maximal electroshock seizures test2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Defining the structural parameters that confer anticonvulsant activity by the site-by-site modification of (R)-N'-benzyl 2-amino-3-methylbutanamide.
AID128173Antagonism of mercaptopropionic acid (MPA) induced convulsions in mouse1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
A novel class of "GABAergic" agents: 1-aryl-3-(aminoalkylidene)oxindoles.
AID128134Ability to inhibit seizures induced by mercaptopropionic acid in mice administered per orally1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis and anticonvulsant and sedative-hypnotic activity of 4-(alkylimino)-2,3-dihydro-4H-1-benzopyrans and -benzothiopyrans.
AID1193694Toxicity in ip dosed mouse assessed as dose required to cause sedation administered 20 mins prior to PTZ challenge relative to control2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Synthesis, anticonvulsant activity and molecular modeling study of some new hydrazinecarbothioamide, benzenesulfonohydrazide, and phenacylacetohydrazide analogues of 4(3H)-quinazolinone.
AID475795Neurotoxicity in po dosed Sprague-Dawley rat assessed as time of peak effect by rotarod test2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Lacosamide isothiocyanate-based agents: novel agents to target and identify lacosamide receptors.
AID1563906Anticonvulsive activity in pentylenetetrazole-induced seizure albino mouse model assessed as lifetime of animal to death at 300 mg/kg, ig administered 30 mins prior to pentylenetetrazole challenge and mesured for 60 mins (Rvb = 17.45 +/- 1.85 min)2019European journal of medicinal chemistry, Oct-15, Volume: 180Synthesis, in vivo and in silico anticonvulsant activity studies of new derivatives of 2-(2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)acetamide.
AID1292443Plasma concentration in healthy human subjects (6 subjects) at 600 mg, po administered as single enteric-coated compound dose measured after 3 hrs by GLC method1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID1292472Half life in human measured over 24 hrs1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID682315Neurotoxicity in mouse assessed as motor impairment at 30 mg/kg, ip after 0.5 hrs by rotarod test2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis of some novel 1-(2-naphthyl)-2-(imidazol-1-yl)ethanone oxime ester derivatives and evaluation of their anticonvulsant activity.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1161078Anticonvulsant activity in ip dosed corneal kindled albino CF1 mouse seizure model2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Novel fluorinated pyrrolo[1,2-a]pyrazine-2,6-dione derivatives: synthesis and anticonvulsant evaluation in animal models of epilepsy.
AID1655741Cytotoxicity against human M193 cells assessed as reduction in cell viability at 0.8 to 6 mM measured after 72 hrs by Celltiter-Glo luminescent assay2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
Predictive Gene Signature for Pyrazolopyrimidine Derivative c-Src Inhibitor 10a Sensitivity in Melanoma Cells.
AID682356Anticonvulsant activity in mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 100 mg/kg, ip after 4 hrs2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis of some novel 1-(2-naphthyl)-2-(imidazol-1-yl)ethanone oxime ester derivatives and evaluation of their anticonvulsant activity.
AID366627Neurotoxicity in ip dosed mouse by rotarod test2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Anticonvulsant activity of some xanthone derivatives.
AID475790Anticonvulsant activity against maximal electroshock-induced seizures in ip dosed albino mouse assessed as time of peak effect2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Lacosamide isothiocyanate-based agents: novel agents to target and identify lacosamide receptors.
AID480292Anticonvulsant activity in po dosed Sprague-Dawley albino rat assessed as inhibition of maximal electroshock-induced seizures after 0.5 hrs2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities.
AID621622Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against maximal electroshock-induced seizures in presence of 50 miliamperes of electric current2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Defining the structural parameters that confer anticonvulsant activity by the site-by-site modification of (R)-N'-benzyl 2-amino-3-methylbutanamide.
AID1292466Drug excretion in urine of healthy human subjects (6 subjects) assessed as VPA-conjugates level at 600 mg, po administered as single enteric-coated compound measured during 0 to 72 hrs relative to total drug excretion1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID449304Anticonvulsant activity in ip dosed albino mouse assessed as inhibition of maximal electric shock-induced seizures after 4 hrs2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, anticonvulsant and CNS depressant activity of some new bioactive 1-(4-substituted-phenyl)-3-(4-oxo-2-phenyl/ethyl-4H-quinazolin-3-yl)-urea.
AID71287Displacement of [3H]gamma-amino butyric acid from Gamma-aminobutyric acid (GABA-A) receptor of human cerebellar cortex preparation1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
New anticonvulsants: Schiff bases of gamma-aminobutyric acid and gamma-aminobutyramide.
AID443563Anticonvulsant activity in po dosed albino Sprague-Dawley rat seizure model assessed as protection against hind limb extension by MES test2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Synthesis and anticonvulsant activities of (R)-N-(4'-substituted)benzyl 2-acetamido-3-methoxypropionamides.
AID366586Protective index, ratio of TD50 for mouse by rotarod test to ED50 for mouse by MES test2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Anticonvulsant activity of some xanthone derivatives.
AID443571Anticonvulsant activity against in ip dosed albino Sprague-Dawley rat hippocampal kindled seizure model assessed as decrease in seizures after 0.5 hrs2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Synthesis and anticonvulsant activities of (R)-N-(4'-substituted)benzyl 2-acetamido-3-methoxypropionamides.
AID1292483Cmax in epileptic patient (6 patients) at 800 mg, po administered as single dose by gas liquid chromatographic method1978British journal of clinical pharmacology, Jun, Volume: 5, Issue:6
Disposition of sodium valproate in epileptic patients.
AID650784Anticonvulsant activity in ip dosed mouse assessed as protection against pentylenetetrazol-induced seizure administered 30 min prior to pentylenetetrazol-challenge measured after 60 mins2012Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
Design and synthesis of novel 7-aminoquinazoline derivatives: antitumor and anticonvulsant activities.
AID509492Anticonvulsant activity in ip dosed albino mouse assessed as protection against MES-induced seizures after 4 hrs2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Design & synthesis of 2-(substituted aryloxy)-5-(substituted benzylidene)-3-phenyl-2,5-dihydro-1H-[1,2,4] triazin-6-one as potential anticonvulsant agents.
AID1292517Total serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 0.66 hrs by gas liquid chromatography
AID1174998Anticonvulsant activity in ip dosed Swiss CF1 mouse measured after 4 hrs by MES test2014Bioorganic & medicinal chemistry letters, Dec-15, Volume: 24, Issue:24
Microwave assisted synthesis and docking study of N-(2-oxo-2-(4-oxo-2-substituted thiazolidin-3ylamino)ethyl)benzamide derivatives as anticonvulsant agents.
AID1292493Half life in healthy volunteer (6 volunteers) at 800 mg, iv administered as single dose by gas liquid chromatographic method1978British journal of clinical pharmacology, Jun, Volume: 5, Issue:6
Disposition of sodium valproate in epileptic patients.
AID625738Anticonvulsant activity in Swiss albino CF1 mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 30 to 300 mg/kg, ip after 4 hrs postdose2011European journal of medicinal chemistry, Nov, Volume: 46, Issue:11
Design and synthesis of 2-(1, 3-dioxoisoindolin-2-yl)-N-(4-oxo-2-substitutedthiazolidin-3-yl) acetamide derivatives as potential anticonvulsant agents.
AID1292488Volume of distribution (area) in epileptic patient (6 patients) at 800 mg, po administered as single dose by gas liquid chromatographic method1978British journal of clinical pharmacology, Jun, Volume: 5, Issue:6
Disposition of sodium valproate in epileptic patients.
AID232953Inhibitory activity measured against pig kidney aldehyde reductase using 3-pyridinecarboxaldehyde as substrate1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
A highly specific aldose reductase inhibitor, ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate, and its congeners.
AID364305Neurotoxicity in mouse assessed as minimal motor impairment at 300 mg/kg, ip after 4 hrs by rotarod test2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
CNS depressant and anticonvulsant activities of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones.
AID650782Therapeutic index, ratio of LD50 for mouse to ED50 for pentylenetetrazol-induced seizure in mouse2012Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
Design and synthesis of novel 7-aminoquinazoline derivatives: antitumor and anticonvulsant activities.
AID449307Neurotoxicity in ip dosed albino mouse assessed as minimal motor impairment after 4 hrs by rotarod test2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, anticonvulsant and CNS depressant activity of some new bioactive 1-(4-substituted-phenyl)-3-(4-oxo-2-phenyl/ethyl-4H-quinazolin-3-yl)-urea.
AID1574763Anticonvulsant activity in po dosed maximal electroshock induced seizure mouse model assessed as reduction in convulsions2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
Identification of 2-(2'-fluoro-[1,1'-biphenyl]-2-yl)acetamide as a Sodium Valproate-like broad spectrum anti-epileptic drug candidate.
AID74542Tested for activation of Glutamate decarboxylase; the ratio of Vmax in the presence of activators to the Vmax in the absence of activators at a concentration of 1.0 mM.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
3-Alkyl-4-aminobutyric acids: the first class of anticonvulsant agents that activates L-glutamic acid decarboxylase.
AID750674Anticonvulsant activity in ip dosed albino CF-1 mouse assessed as protection against subcutaneous metrazole-induced seizures in half or more animals after 0.5 hrs2013European journal of medicinal chemistry, Jun, Volume: 64Augmentation of GABAergic neurotransmission by novel N-(substituted)-2-[4-(substituted)benzylidene]hydrazinecarbothioamides-a potential anticonvulsant approach.
AID1161068Anticonvulsant activity in ip dosed Sprague-Dawley rat assessed as protection against maximal electroshock-induced seizures measured as time to peak effect2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Novel fluorinated pyrrolo[1,2-a]pyrazine-2,6-dione derivatives: synthesis and anticonvulsant evaluation in animal models of epilepsy.
AID364287Anticonvulsant activity in mouse at 300 mg/kg, ip after 0.5 hrs by MES test2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
CNS depressant and anticonvulsant activities of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones.
AID569168Anticonvulsant activity in ip dosed albino CF-1 mouse assessed as dose required to protect against subcutaneous metrazol-induced seizures after 0.5 hrs2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Design & synthesis of N'-[substituted] pyridine-4-carbohydrazides as potential anticonvulsant agents.
AID1292515Fraction unbound in healthy human (6 volunteers) serum at 1 g, po administered as single dose
AID1292536Unbound serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 1.5 hrs by enzyme multiple immunotechnique
AID1292561Fraction unbound in healthy human (6 volunteers) serum at 1 g, po administered as single dose measured after 12 hrs
AID1193695Protective index, ratio of TD50 for mouse to ED50 for anticonvulsant activity in mouse2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Synthesis, anticonvulsant activity and molecular modeling study of some new hydrazinecarbothioamide, benzenesulfonohydrazide, and phenacylacetohydrazide analogues of 4(3H)-quinazolinone.
AID509485Anticonvulsant activity in ip dosed albino mouse assessed as protection against scPTZ-induced seizures after 30 mins2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
N'-[(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene] 2/4-substituted hydrazides: synthesis and anticonvulsant activity.
AID682343Anticonvulsant activity in mouse assessed as protection against maximal electroshock-induced seizures at 100 mg/kg, ip after 0.5 hrs2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis of some novel 1-(2-naphthyl)-2-(imidazol-1-yl)ethanone oxime ester derivatives and evaluation of their anticonvulsant activity.
AID1292549Unbound serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 48 hrs by enzyme multiple immunotechnique
AID443564Behavioral toxicity in po dosed albino Sprague-Dawley rat2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Synthesis and anticonvulsant activities of (R)-N-(4'-substituted)benzyl 2-acetamido-3-methoxypropionamides.
AID665954Protective index, ratio of TD50 for NMRI mouse to ED50 for anticonvulsant activity in ip dosed NMRI mouse by maximal electroshock seizure test2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Synthesis, anticonvulsant activity, and neuropathic pain-attenuating activity of N-benzyl 2-amino-2-(hetero)aromatic acetamides.
AID34179Selectivity ratio measured as the IC50 ratio of aldehyde/aldose reductase values1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
A highly specific aldose reductase inhibitor, ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate, and its congeners.
AID1292494Volume of distribution (area) in healthy volunteer (6 volunteers) at 800 mg, iv administered as single dose by gas liquid chromatographic method1978British journal of clinical pharmacology, Jun, Volume: 5, Issue:6
Disposition of sodium valproate in epileptic patients.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID449303Anticonvulsant activity in ip dosed albino mouse assessed as inhibition of maximal electric shock-induced seizures after 0.5 hrs2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, anticonvulsant and CNS depressant activity of some new bioactive 1-(4-substituted-phenyl)-3-(4-oxo-2-phenyl/ethyl-4H-quinazolin-3-yl)-urea.
AID1292520Total serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 2 hrs by gas liquid chromatography
AID639223Anticonvulsant activity in Swiss albino mouse assessed as protection against maximal electroshock-induced seizure at 300 mg/kg, ip administered 30 mins before challenge2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Synthesis and anticonvulsant evaluation of some new 2,3,8-trisubstituted-4(3H)-quinazoline derivatives.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID477357Anticonvulsant activity in ip dosed Swiss albino mouse assessed as inhibition of maximum electric shock-induced motor impairment2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
Triazole incorporated thiazoles as a new class of anticonvulsants: design, synthesis and in vivo screening.
AID1720862Anticonvulsant activity in ip injected albino mouse assessed as protection against 50 mA current-induced seizure after 0.5 to 4 hrs interval by maximal electroshock seizure test2020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Synthetic and therapeutic perspectives of nitrogen containing heterocycles as anti-convulsants.
AID443565Protective index, ratio of TD50 for po dosed albino Sprague-Dawley rat to ED50 for po dosed albino Sprague-Dawley rat2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Synthesis and anticonvulsant activities of (R)-N-(4'-substituted)benzyl 2-acetamido-3-methoxypropionamides.
AID693326Protective index, ratio of TD50 for mouse to ED50 for anticonvulsant activity in mouse by maximal electroshock-seizure test2012European journal of medicinal chemistry, Dec, Volume: 58Design, synthesis and evaluation of N-(substituted benzothiazol-2-yl)amides as anticonvulsant and neuroprotective.
AID1489008Therapeutic index, ratio of TD50 for neurotoxicity in po dosed mouse to ED50 for po dosed maximal electroshock induced seizure mouse model2017Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
N-alkyl-[1,1'-biphenyl]-2-sulfonamide derivatives as novel broad spectrum anti-epileptic drugs with efficacy equivalent to that of sodium valproate.
AID619692Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against maximal electroshock-induced seizure after 30 mins2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Primary amino acid derivatives: substitution of the 4'-N'-benzylamide site in (R)-N'-benzyl 2-amino-3-methylbutanamide, (R)-N'-benzyl 2-amino-3,3-dimethylbutanamide, and (R)-N'-benzyl 2-amino-3-methoxypropionamide provides potent anticonvulsants with pain
AID1292535Unbound serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 1 hr by enzyme multiple immunotechnique
AID1292446Plasma concentration in healthy human subjects (6 subjects) at 600 mg, po administered as single enteric-coated compound dose measured after 10 hrs by GLC method1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID682355Anticonvulsant activity in mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 300 mg/kg, ip after 4 hrs2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis of some novel 1-(2-naphthyl)-2-(imidazol-1-yl)ethanone oxime ester derivatives and evaluation of their anticonvulsant activity.
AID387786Protective index, ratio of TD50 for albino mouse by rotarod test to ED50 for albino mouse by MES seizure test2008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Synthesis and anticonvulsant activities of N-benzyl (2R)-2-acetamido-3-oxysubstituted propionamide derivatives.
AID477728Protective index, ratio of TD50 for neurotoxicity in Swiss albino mouse to ED50 for inhibition of PTZ-induced motor impairment Swiss albino mouse2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
Triazole incorporated thiazoles as a new class of anticonvulsants: design, synthesis and in vivo screening.
AID1292559Fraction unbound in healthy human (6 volunteers) serum at 1 g, po administered as single dose measured after 8 hrs
AID1193693Anticonvulsant activity in ip dosed mouse assessed as protection against PTZ-induced convulsions administered 20 mins prior to PTZ challenge relative to control2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Synthesis, anticonvulsant activity and molecular modeling study of some new hydrazinecarbothioamide, benzenesulfonohydrazide, and phenacylacetohydrazide analogues of 4(3H)-quinazolinone.
AID1161070Anticonvulsant activity in ip dosed Sprague-Dawley rat assessed as protection against subcutaneous metrazol-induced seizures measured at 0.25 hr post dose2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Novel fluorinated pyrrolo[1,2-a]pyrazine-2,6-dione derivatives: synthesis and anticonvulsant evaluation in animal models of epilepsy.
AID1292487Extrapolated volume of distribution in epileptic patient (6 patients) at 800 mg, po administered as single dose by gas liquid chromatographic method1978British journal of clinical pharmacology, Jun, Volume: 5, Issue:6
Disposition of sodium valproate in epileptic patients.
AID682320Neurotoxicity in mouse assessed as motor impairment at 300 mg/kg, ip after 4 hrs by rotarod test2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis of some novel 1-(2-naphthyl)-2-(imidazol-1-yl)ethanone oxime ester derivatives and evaluation of their anticonvulsant activity.
AID489280Anticonvulsant activity against subcutaneous strychnine-induced seizures in ip dosed Wistar rat assessed as minimum effective dose after 0.5 hrs2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Novel semicarbazones based 2,5-disubstituted-1,3,4-oxadiazoles: one more step towards establishing four binding site pharmacophoric model hypothesis for anticonvulsant activity.
AID682345Anticonvulsant activity in mouse assessed as protection against maximal electroshock-induced seizures at 30 mg/kg, ip after 4 hrs2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis of some novel 1-(2-naphthyl)-2-(imidazol-1-yl)ethanone oxime ester derivatives and evaluation of their anticonvulsant activity.
AID74545Tested for activation of Glutamate decarboxylase; the ratio of Vmax in the presence of activators to the Vmax in the absence of activators at a concentration of 250 uM.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
3-Alkyl-4-aminobutyric acids: the first class of anticonvulsant agents that activates L-glutamic acid decarboxylase.
AID1175001Neurotoxicity in ip dosed Swiss CF1 mouse assessed as induction of motor impairment measured after 0.5 hrs by rotorod test2014Bioorganic & medicinal chemistry letters, Dec-15, Volume: 24, Issue:24
Microwave assisted synthesis and docking study of N-(2-oxo-2-(4-oxo-2-substituted thiazolidin-3ylamino)ethyl)benzamide derivatives as anticonvulsant agents.
AID509487Anticonvulsant activity in ip dosed albino mouse assessed as protection against MES-induced seizures after 4 hrs2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
N'-[(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene] 2/4-substituted hydrazides: synthesis and anticonvulsant activity.
AID637076Protective index, ratio of TD50 for ip dosed Kunming mouse to ED50 for ip dosed Kunming mouse by subcutaneous pentylenetetrazole induced seizure test2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and anticonvulsant activity of 1-(8-(benzyloxy)quinolin-2-yl)-6-substituted-4,6-diazaspiro[2,4]heptane-5,7-diones.
AID1292444Plasma concentration in healthy human subjects (6 subjects) at 600 mg, po administered as single enteric-coated compound dose measured after 4 hrs by GLC method1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID1563905Anticonvulsive activity in pentylenetetrazole-induced seizure albino mouse model assessed as duration time of convulsion period at 300 mg/kg, ig administered 30 mins prior to pentylenetetrazole challenge and mesured for 60 mins (Rvb = 12 +/- 1.34 min)2019European journal of medicinal chemistry, Oct-15, Volume: 180Synthesis, in vivo and in silico anticonvulsant activity studies of new derivatives of 2-(2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)acetamide.
AID1292552Fraction unbound in healthy human (6 volunteers) serum at 1 g, po administered as single dose measured after 1 hr
AID1292473Apparent volume of distribution in healthy human subjects (6 subjects) assessed as volume of distribution based on protein binding corrected AUC at 600 mg, po administered as single enteric-coated compound dose measured by GLC method1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID1161065Anticonvulsant activity in ip dosed Sprague-Dawley rat assessed as protection against subcutaneous metrazol-induced seizures2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Novel fluorinated pyrrolo[1,2-a]pyrazine-2,6-dione derivatives: synthesis and anticonvulsant evaluation in animal models of epilepsy.
AID682318Neurotoxicity in mouse assessed as motor impairment at 30 mg/kg, ip after 4 hrs by rotarod test2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis of some novel 1-(2-naphthyl)-2-(imidazol-1-yl)ethanone oxime ester derivatives and evaluation of their anticonvulsant activity.
AID1292540Unbound serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 5 hrs by enzyme multiple immunotechnique
AID1292445Plasma concentration in healthy human subjects (6 subjects) at 600 mg, po administered as single enteric-coated compound dose measured after 6 hrs by GLC method1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID619781Neurotoxicity in ip dosed albino CF1 mouse assessed as time of peak effect for median neurological impairing2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Primary amino acid derivatives: substitution of the 4'-N'-benzylamide site in (R)-N'-benzyl 2-amino-3-methylbutanamide, (R)-N'-benzyl 2-amino-3,3-dimethylbutanamide, and (R)-N'-benzyl 2-amino-3-methoxypropionamide provides potent anticonvulsants with pain
AID475791Protective index, ratio of TD50 for ip dosed albino mouse to ED50 for protection against maximal electroshock-induced seizures in ip dosed albino mouse2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Lacosamide isothiocyanate-based agents: novel agents to target and identify lacosamide receptors.
AID110224Ability to prevent the tonic extensor component induced by 106.25 mg/kg sc of pentylenetetrazole; Percentage of protection at 100 mg/kg per os.1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Synthesis and anticonvulsant properties of new benzylpyridazine derivatives.
AID1292452Tmax in healthy human subjects (6 subjects) at 600 mg, po administered as single enteric-coated compound dose measured by GLC method1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID750677Anticonvulsant activity in albino CF-1 mouse at 300 mg/kg, ip assessed as protection against maximal electroshock-induced seizures in half or more animals after 4 hrs2013European journal of medicinal chemistry, Jun, Volume: 64Augmentation of GABAergic neurotransmission by novel N-(substituted)-2-[4-(substituted)benzylidene]hydrazinecarbothioamides-a potential anticonvulsant approach.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1292518Total serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 1 hr by gas liquid chromatography
AID1292524Total serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 6 hrs by gas liquid chromatography
AID449311Anticonvulsant activity in ip dosed albino mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizure after 4 hrs2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, anticonvulsant and CNS depressant activity of some new bioactive 1-(4-substituted-phenyl)-3-(4-oxo-2-phenyl/ethyl-4H-quinazolin-3-yl)-urea.
AID74543Compound was tested for activation of Glutamate decarboxylase which is the ratio of Vmax in the presence of activators to the Vmax in the absence of activators at a concentration of 100 uM.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
3-Alkyl-4-aminobutyric acids: the first class of anticonvulsant agents that activates L-glutamic acid decarboxylase.
AID1292550Fraction unbound in healthy human (6 volunteers) serum at 1 g, po administered as single dose measured after 0.33 hrs
AID1358193Anticonvulsant activity in Swiss albino mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 300 mg/kg, ip administered 4 hrs prior to PTZ challenge and measured after 30 mins2018European journal of medicinal chemistry, May-10, Volume: 151Discovery of novel Methylsulfonyl phenyl derivatives as potent human Cyclooxygenase-2 inhibitors with effective anticonvulsant action: Design, synthesis, in-silico, in-vitro and in-vivo evaluation.
AID650794Anticonvulsant activity in mouse assessed as protection against pentylenetetrazol-induced seizure at 1.5 mmol/kg, ip administered 30 min prior to pentylenetetrazol-challenge measured after 60 mins relative to control2012Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
Design and synthesis of novel 7-aminoquinazoline derivatives: antitumor and anticonvulsant activities.
AID1292451Drug lag time in healthy human subjects (6 subjects) at 600 mg, po administered as single enteric-coated compound dose measured by GLC method1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID1292525Total serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 8 hrs by gas liquid chromatography
AID1574764Anticonvulsant activity in po dosed subcutaneous pentylenetetrazole-induced seizure mouse model assessed as reduction in convulsions2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
Identification of 2-(2'-fluoro-[1,1'-biphenyl]-2-yl)acetamide as a Sodium Valproate-like broad spectrum anti-epileptic drug candidate.
AID121847Central nervous system toxicity was performed by determining the median toxic dose in the rotarod test1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Synthesis and anticonvulsant properties of new benzylpyridazine derivatives.
AID114817Sedative properties by the rotarod test1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and activity of 6-aryl-3-(hydroxypolymethyleneamino)pyridazines in animal models of epilepsy.
AID727852Antiepileptic activity in Wistar rat assessed as protection against scSTY-induced seizures at 300 mg/kg, ip measured after 4 hrs2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Novel limonene and citral based 2,5-disubstituted-1,3,4-oxadiazoles: a natural product coupled approach to semicarbazones for antiepileptic activity.
AID1185525Toxicity in ip dosed Kunming mouse assessed as inability of animal to maintain equilibrium on rod for at least 1 min in each trial by rotarod test2014European journal of medicinal chemistry, Sep-12, Volume: 84Synthesis and anticonvulsant activity of novel purine derivatives.
AID682316Neurotoxicity in mouse assessed as motor impairment at 100 mg/kg, ip after 0.5 hrs by rotarod test2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis of some novel 1-(2-naphthyl)-2-(imidazol-1-yl)ethanone oxime ester derivatives and evaluation of their anticonvulsant activity.
AID449306Neurotoxicity in ip dosed albino mouse assessed as minimal motor impairment after 0.5 hrs by rotarod test2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, anticonvulsant and CNS depressant activity of some new bioactive 1-(4-substituted-phenyl)-3-(4-oxo-2-phenyl/ethyl-4H-quinazolin-3-yl)-urea.
AID1177949Protective index, ratio of neurotoxicity in mouse by rotarod test to ED50 for inhibition of maximal electroshock-induced seizures in mouse2014European journal of medicinal chemistry, Apr-09, Volume: 76Recent advances in the structural library of functionalized quinazoline and quinazolinone scaffolds: synthetic approaches and multifarious applications.
AID1292548Unbound serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 39 hrs by enzyme multiple immunotechnique
AID74547Compound was tested for activation of Glutamate decarboxylase which is the ratio of Vmax in the presence of activators to the Vmax in the absence of activators at a concentration of 50 uM.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
3-Alkyl-4-aminobutyric acids: the first class of anticonvulsant agents that activates L-glutamic acid decarboxylase.
AID114622Evaluated for Bicuculline-induced lethality (anticonvulsant activity) when administered orally in mice.1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and activity of 6-aryl-3-(hydroxypolymethyleneamino)pyridazines in animal models of epilepsy.
AID1292474Initial plasma concentration in epileptic patient (6 patients) at 800 mg, iv administered as single dose by gas liquid chromatographic method1978British journal of clinical pharmacology, Jun, Volume: 5, Issue:6
Disposition of sodium valproate in epileptic patients.
AID477359Protective index, ratio of TD50 for neurotoxicity in Swiss albino mouse to ED50 for inhibition of maximal electroshock-induced seizures Swiss albino mouse2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
Triazole incorporated thiazoles as a new class of anticonvulsants: design, synthesis and in vivo screening.
AID1292449Plasma concentration in healthy human subjects (6 subjects) at 600 mg, po administered as single enteric-coated compound dose measured after 48 hrs by GLC method1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID1292529Total serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 24 hrs by gas liquid chromatography
AID1563916Toxicity in albino mouse assessed as motor coordination impairment by measuring animal fall-off from rod before 1 min at 300 mg/kg, ig administered 30 mins prior to test by rotarod test (Rvb = 17%)2019European journal of medicinal chemistry, Oct-15, Volume: 180Synthesis, in vivo and in silico anticonvulsant activity studies of new derivatives of 2-(2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)acetamide.
AID509496Neurotoxicity against ip dosed albino mouse assessed as inability of animal to maintain equilibrium on rod for 1 min after 4 hrs by rotarod test2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Design & synthesis of 2-(substituted aryloxy)-5-(substituted benzylidene)-3-phenyl-2,5-dihydro-1H-[1,2,4] triazin-6-one as potential anticonvulsant agents.
AID682317Neurotoxicity in mouse assessed as motor impairment at 300 mg/kg, ip after 0.5 hrs by rotarod test2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis of some novel 1-(2-naphthyl)-2-(imidazol-1-yl)ethanone oxime ester derivatives and evaluation of their anticonvulsant activity.
AID637069Neurotoxicity in ip dosed Kunming mouse assessed as minimal motor impairment after 0.5 hrs by rotarod test2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and anticonvulsant activity of 1-(8-(benzyloxy)quinolin-2-yl)-6-substituted-4,6-diazaspiro[2,4]heptane-5,7-diones.
AID475784Neurotoxicity in ip dosed albino mouse assessed as time of peak effect by rotarod test2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Lacosamide isothiocyanate-based agents: novel agents to target and identify lacosamide receptors.
AID1074412Neurotoxicity in KunMing mouse assessed as motor impairment at 300 mg/kg, ip after 0.5 hrs by rotarod test2014European journal of medicinal chemistry, Feb-12, Volume: 73Design, synthesis and evaluation of the antidepressant and anticonvulsant activities of triazole-containing quinolinones.
AID74544Tested for activation of Glutamate decarboxylase; the ratio of Vmax in the presence of activators to the Vmax in the absence of activators at a concentration of 2.5 mM.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
3-Alkyl-4-aminobutyric acids: the first class of anticonvulsant agents that activates L-glutamic acid decarboxylase.
AID1292458Total plasma clearance in healthy human subjects (6 subjects) at 600 mg, po administered as single enteric-coated compound dose measured by GLC method1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID90359Concentration required for inhibition of histone deacetylase HD2 in vitro.2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 2. Effect of pyrrole-C2 and/or -C4 substitutions on biological activity.
AID619696Protective index, ratio of TD50 for ip dosed albino CF1 mouse to ED50 for ip dosed albino CF1 mouse by maximal electroshock test2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Primary amino acid derivatives: substitution of the 4'-N'-benzylamide site in (R)-N'-benzyl 2-amino-3-methylbutanamide, (R)-N'-benzyl 2-amino-3,3-dimethylbutanamide, and (R)-N'-benzyl 2-amino-3-methoxypropionamide provides potent anticonvulsants with pain
AID765791Teratogenicity in SWV/Fnn mouse assessed as live fetuses at 181 mg/kg, ip on day 8.5 of gestation (Rvb = 93.7 %)2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID114623Evaluated for Bicuculline-induced seizures (anticonvulsant activity) when administered orally in mice.1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and activity of 6-aryl-3-(hydroxypolymethyleneamino)pyridazines in animal models of epilepsy.
AID1292521Total serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 3 hrs by gas liquid chromatography
AID1563917Toxicity in albino mouse assessed as motor coordination impairment by measuring animal fall-off from rod before 2 mins at 300 mg/kg, ig administered 30 mins prior to test by rotarod test (Rvb = 33%)2019European journal of medicinal chemistry, Oct-15, Volume: 180Synthesis, in vivo and in silico anticonvulsant activity studies of new derivatives of 2-(2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)acetamide.
AID443567Anticonvulsant activity against subcutaneous metrazole-induced seizures in albino CF1 mouse at 300 mg/kg, ip after 0.5 hrs2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Synthesis and anticonvulsant activities of (R)-N-(4'-substituted)benzyl 2-acetamido-3-methoxypropionamides.
AID1175000Anticonvulsant activity in ip dosed Swiss CF1 mouse measured after 4 hrs by scPTZ test2014Bioorganic & medicinal chemistry letters, Dec-15, Volume: 24, Issue:24
Microwave assisted synthesis and docking study of N-(2-oxo-2-(4-oxo-2-substituted thiazolidin-3ylamino)ethyl)benzamide derivatives as anticonvulsant agents.
AID1292479Apparent volume of distribution in epileptic patient (6 patients) at 800 mg, iv administered as single dose by gas liquid chromatographic method1978British journal of clinical pharmacology, Jun, Volume: 5, Issue:6
Disposition of sodium valproate in epileptic patients.
AID569078Anticonvulsant activity in albino CF-1 mouse assessed as protection against maximal electroshock-induced seizures at 300 mg/kg, ip after 2 hrs2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Design & synthesis of N'-[substituted] pyridine-4-carbohydrazides as potential anticonvulsant agents.
AID1292461Half life at steady state in healthy human subjects (6 subjects) at 1200 mg, po for 12 days administered as enteric-coated compound dose by GLC method1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID1292543Unbound serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 10 hrs by enzyme multiple immunotechnique
AID1292478Volume of distribution (area) in epileptic patient (6 patients) at 800 mg, iv administered as single dose by gas liquid chromatographic method1978British journal of clinical pharmacology, Jun, Volume: 5, Issue:6
Disposition of sodium valproate in epileptic patients.
AID1275691Anticonvulsant activity in ip dosed Kunming mouse assessed as protection against maximal electroshock-induced seizures assessed during phase 2 inflammatory phase2016European journal of medicinal chemistry, Feb-15, Volume: 109The importance of triazole scaffold in the development of anticonvulsant agents.
AID621649Anticonvulsant activity in po dosed albino Sprague-Dawley rat assessed as protection against maximal electroshock-induced seizures in presence of 150 miliamperes of electric current2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Defining the structural parameters that confer anticonvulsant activity by the site-by-site modification of (R)-N'-benzyl 2-amino-3-methylbutanamide.
AID123954Locomotor activity in maximal electroshock seizure. - indicates decrease at 100 mg/kg1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Synthesis and anticonvulsant properties of new benzylpyridazine derivatives.
AID1174997Anticonvulsant activity in ip dosed Swiss CF1 mouse measured after 0.5 hrs by MES test2014Bioorganic & medicinal chemistry letters, Dec-15, Volume: 24, Issue:24
Microwave assisted synthesis and docking study of N-(2-oxo-2-(4-oxo-2-substituted thiazolidin-3ylamino)ethyl)benzamide derivatives as anticonvulsant agents.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID1292563Fraction unbound in healthy human (6 volunteers) serum at 1 g, po administered as single dose measured after 24 hrs
AID117219Lethal dose which causes death in 50% of the mice within 48 hr of ip administration1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
New anticonvulsants: Schiff bases of gamma-aminobutyric acid and gamma-aminobutyramide.
AID1292480AUC (0 to 48 hrs) in epileptic patient (6 patients) at 800 mg, iv administered as single dose by gas liquid chromatographic method1978British journal of clinical pharmacology, Jun, Volume: 5, Issue:6
Disposition of sodium valproate in epileptic patients.
AID480288Protective index, ratio of TD50 for albino mouse to anticonvulsant ED50 for albino mouse2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities.
AID480303Anticonvulsant activity in albino mouse assessed as protection against subcutaneous metrazole-induced seizures up to 300 mg/kg, ip after 4 hrs2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities.
AID1292534Unbound serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 0.66 hrs by enzyme multiple immunotechnique
AID569169Neurotoxicity in albino CF-1 mouse assessed as motor impairment at 300 mg/kg, ip after 0.5 hrs by rotarod test2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Design & synthesis of N'-[substituted] pyridine-4-carbohydrazides as potential anticonvulsant agents.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1292541Unbound serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 6 hrs by enzyme multiple immunotechnique
AID128136Ability to inhibit seizures induced by pentylenetetrazole in mice administered per orally1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis and anticonvulsant and sedative-hypnotic activity of 4-(alkylimino)-2,3-dihydro-4H-1-benzopyrans and -benzothiopyrans.
AID1143178Neurotoxicity in Swiss albino mouse assessed as motor impairment at 100 mg/kg, po by rotarod test2014European journal of medicinal chemistry, Jun-10, Volume: 80Anticonvulsant evaluation of clubbed indole-1,2,4-triazine derivatives: a synthetic approach.
AID619699Protective index, ratio of TD50 for po dosed albino Sprague-Dawley rat to ED50 for po dosed albino Sprague-Dawley rat by maximal electroshock test2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Primary amino acid derivatives: substitution of the 4'-N'-benzylamide site in (R)-N'-benzyl 2-amino-3-methylbutanamide, (R)-N'-benzyl 2-amino-3,3-dimethylbutanamide, and (R)-N'-benzyl 2-amino-3-methoxypropionamide provides potent anticonvulsants with pain
AID364293Anticonvulsant activity in mouse at 300 mg/kg, ip after 4 hrs by scPTZ test2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
CNS depressant and anticonvulsant activities of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones.
AID1292497Tmax in healthy volunteer (6 volunteers) at 800 mg, po administered as single dose by gas liquid chromatographic method1978British journal of clinical pharmacology, Jun, Volume: 5, Issue:6
Disposition of sodium valproate in epileptic patients.
AID382388Neurotoxicity in mouse at 300 mg/kg, ip after 4 hrs by rotarod test2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Synthesis and CNS depressant activity of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones.
AID1292467Drug excretion in urine of healthy human subjects (6 subjects) assessed as valproic acid level at 600 mg, po administered as single enteric-coated compound measured during 0 to 72 hrs relative to total drug excretion1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1292463Plasma protein binding in healthy human subjects (6 subjects) assessed as unbound fraction level measured under steady state conditions by equilibrium dialysis method1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID395123Anticonvulsant activity in mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures at 40 mg/kg, po2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Synthesis and potential anticonvulsant activity of new N-3-substituted 5,5-cyclopropanespirohydantoins.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID263284Seizure latency in PTZ-induced lethal convulsions in mice at 150 mg/kg, ip2006Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
Azolylchromans as a novel scaffold for anticonvulsant activity.
AID1292465Drug concentration in saliva of healthy human subjects (6 subjects) at 1200 mg, po for 12 days administered as enteric-coated compound dose measured under steady state conditions by GLC method relative to plasma drug level1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID1193702Anticonvulsant activity in mouse assessed as protection against PTZ-induced convulsions at 50 mg/kg, ip administered 20 mins prior to PTZ challenge relative to control2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Synthesis, anticonvulsant activity and molecular modeling study of some new hydrazinecarbothioamide, benzenesulfonohydrazide, and phenacylacetohydrazide analogues of 4(3H)-quinazolinone.
AID638641Neurotoxicity in albino CF-1 mouse assessed as minimum motor impairment at 300 mg/kg, ip after 0.5 hrs by rotarod test2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Design, synthesis and anticonvulsant evaluation of novel N-(4-substituted phenyl)-2-[4-(substituted) benzylidene]-hydrazinecarbothio amides.
AID545525Protective index, ratio of TD50 for mouse to ED50 for inhibition of maximal electroshock-induced seizure in mouse2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Synthesis and anticonvulsant activity of N-3-arylamide substituted 5,5-cyclopropanespirohydantoin derivatives.
AID382383Anticonvulsant activity in mouse assessed as inhibition of maximal electroshock-induced seizures at 300 mg/kg, ip after 0.5 hrs2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Synthesis and CNS depressant activity of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones.
AID650791Anticonvulsant activity in mouse assessed as protection against strychnine-induced seizure at 1.5 mmol/kg, ip administered 30 min prior to strychnine-challenge measured after 60 mins relative to control2012Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
Design and synthesis of novel 7-aminoquinazoline derivatives: antitumor and anticonvulsant activities.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID650783Neurotoxicity in ip dosed mouse assessed as impaired motor coordination administered 30 mins prior to test by chimney test2012Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
Design and synthesis of novel 7-aminoquinazoline derivatives: antitumor and anticonvulsant activities.
AID1489017Anticonvulsant activity in amygdala kindling rat model assessed as change in after discharge threshold at 600 mg/kg, po relative to control2017Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
N-alkyl-[1,1'-biphenyl]-2-sulfonamide derivatives as novel broad spectrum anti-epileptic drugs with efficacy equivalent to that of sodium valproate.
AID545527Anticonvulsant activity in ip dosed mouse assessed as inhibition of maximum electric shock-induced hind limb tonic extension2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Synthesis and anticonvulsant activity of N-3-arylamide substituted 5,5-cyclopropanespirohydantoin derivatives.
AID1292496Total clearance in healthy volunteer (6 volunteers) at 800 mg, iv administered as single dose by gas liquid chromatographic method1978British journal of clinical pharmacology, Jun, Volume: 5, Issue:6
Disposition of sodium valproate in epileptic patients.
AID1292570Drug metabolism in healthy human (6 volunteers) assessed as excretion of valproic acid glucuronide in urine at 1 g, po administered as single dose measured upto 48 hrs by gas liquid chromatography
AID1563900Anticonvulsive activity in pentylenetetrazole-induced seizure albino mouse model assessed as latency time at 300 mg/kg, ig administered 30 mins prior to pentylenetetrazole challenge and mesured for 60 mins (Rvb = 5.79 +/- 0.58 min)2019European journal of medicinal chemistry, Oct-15, Volume: 180Synthesis, in vivo and in silico anticonvulsant activity studies of new derivatives of 2-(2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)acetamide.
AID1292482Total clearance in epileptic patient (6 patients) at 800 mg, iv administered as single dose by gas liquid chromatographic method1978British journal of clinical pharmacology, Jun, Volume: 5, Issue:6
Disposition of sodium valproate in epileptic patients.
AID509495Neurotoxicity against ip dosed albino mouse assessed as inability of animal to maintain equilibrium on rod for 1 min after 0.5 hrs by rotarod test2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Design & synthesis of 2-(substituted aryloxy)-5-(substituted benzylidene)-3-phenyl-2,5-dihydro-1H-[1,2,4] triazin-6-one as potential anticonvulsant agents.
AID489285Anticonvulsant activity against maximal electroshock-induced seizures in Swiss albino mouse at 300 mg/kg, ip after 4 hrs2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Novel semicarbazones based 2,5-disubstituted-1,3,4-oxadiazoles: one more step towards establishing four binding site pharmacophoric model hypothesis for anticonvulsant activity.
AID1292486Half life in epileptic patient (6 patients) at 800 mg, po administered as single dose by gas liquid chromatographic method1978British journal of clinical pharmacology, Jun, Volume: 5, Issue:6
Disposition of sodium valproate in epileptic patients.
AID1292516Total serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 0.33 hrs by gas liquid chromatography
AID475785Neurotoxicity in ip dosed albino mouse by rotarod test2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Lacosamide isothiocyanate-based agents: novel agents to target and identify lacosamide receptors.
AID638632Anticonvulsant activity in albino CF-1 mouse assessed as protection against maximal electroshock-induced seizures at 300 mg/kg, ip after 0.5 hrs2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Design, synthesis and anticonvulsant evaluation of novel N-(4-substituted phenyl)-2-[4-(substituted) benzylidene]-hydrazinecarbothio amides.
AID475789Anticonvulsant activity in ip dosed albino mouse assessed as protection against maximal electroshock-induced seizures2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Lacosamide isothiocyanate-based agents: novel agents to target and identify lacosamide receptors.
AID1292573Fraction unbound in healthy human (6 volunteers) serum assessed as ratio of fAUC to total AUC at 1 g, po administered as single dose by gas liquid chromatography
AID509486Anticonvulsant activity in ip dosed albino mouse assessed as protection against MES-induced seizures after 30 mins2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
N'-[(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene] 2/4-substituted hydrazides: synthesis and anticonvulsant activity.
AID650781Toxicity in ip dose mouse assessed as mortality2012Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
Design and synthesis of novel 7-aminoquinazoline derivatives: antitumor and anticonvulsant activities.
AID750679Anticonvulsant activity in albino CF-1 mouse at 300 mg/kg, ip assessed as protection against maximal electroshock-induced seizures in half or more animals after 0.5 hrs2013European journal of medicinal chemistry, Jun, Volume: 64Augmentation of GABAergic neurotransmission by novel N-(substituted)-2-[4-(substituted)benzylidene]hydrazinecarbothioamides-a potential anticonvulsant approach.
AID1292565Fraction unbound in healthy human (6 volunteers) serum at 1 g, po administered as single dose measured after 39 hrs
AID765793Teratogenicity in SWV/Fnn mouse assessed as resorption at 181 mg/kg, ip on day 8.5 of gestation (Rvb = 6.3 %)2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID1563919Toxicity in albino mouse assessed as motor coordination impairment by measuring animal fall-off from rod before 5 mins at 300 mg/kg, ig administered 30 mins prior to test by rotarod test (Rvb = 50%)2019European journal of medicinal chemistry, Oct-15, Volume: 180Synthesis, in vivo and in silico anticonvulsant activity studies of new derivatives of 2-(2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)acetamide.
AID366628Anticonvulsant activity against scMet-induced seizures in ip dosed mouse2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Anticonvulsant activity of some xanthone derivatives.
AID480286Toxicity in ip dosed albino mouse after 0.25 hrs by rotarod test2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities.
AID477358Anticonvulsant activity in ip dosed Swiss albino mouse assessed as inhibition of PTZ-induced motor impairment2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
Triazole incorporated thiazoles as a new class of anticonvulsants: design, synthesis and in vivo screening.
AID1292475Elimination rate constant in epileptic patient (6 patients) at 800 mg, iv administered as single dose by gas liquid chromatographic method1978British journal of clinical pharmacology, Jun, Volume: 5, Issue:6
Disposition of sodium valproate in epileptic patients.
AID1292447Plasma concentration in healthy human subjects (6 subjects) at 600 mg, po administered as single enteric-coated compound dose measured after 24 hrs by GLC method1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID625829Neurotoxicity in Swiss albino CF1 mouse assessed as minimal motor deficit at 30 to 300 mg/kg, ip after 4 hrs by rotarod test2011European journal of medicinal chemistry, Nov, Volume: 46, Issue:11
Design and synthesis of 2-(1, 3-dioxoisoindolin-2-yl)-N-(4-oxo-2-substitutedthiazolidin-3-yl) acetamide derivatives as potential anticonvulsant agents.
AID639297Therapeutic index, ratio of LD50 for mortality to ED50 for anticonvulsant activity in Swiss albino mouse2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Synthesis and anticonvulsant evaluation of some new 2,3,8-trisubstituted-4(3H)-quinazoline derivatives.
AID727989Antiepileptic activity in ip dosed Wistar rat assessed as protection against scSTY-induced seizures after 0.5 hrs2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Novel limonene and citral based 2,5-disubstituted-1,3,4-oxadiazoles: a natural product coupled approach to semicarbazones for antiepileptic activity.
AID1489011Anticonvulsant activity in po dosed 6-Hz induced seizure mouse model2017Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
N-alkyl-[1,1'-biphenyl]-2-sulfonamide derivatives as novel broad spectrum anti-epileptic drugs with efficacy equivalent to that of sodium valproate.
AID1292464Drug concentration in saliva of healthy human subjects (6 subjects) at 600 mg, po administered as single enteric-coated compound1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID1292459Mean steady state plasma concentration in healthy human subjects (6 subjects) at 1200 mg, po for 12 days administered as enteric-coated compound dose by GLC method1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID509494Anticonvulsant activity in ip dosed albino mouse assessed as protection against scPTZ-induced seizures after 4 hrs2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Design & synthesis of 2-(substituted aryloxy)-5-(substituted benzylidene)-3-phenyl-2,5-dihydro-1H-[1,2,4] triazin-6-one as potential anticonvulsant agents.
AID1292448Plasma concentration in healthy human subjects (6 subjects) at 600 mg, po administered as single enteric-coated compound dose measured after 30 hrs by GLC method1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID1720864Protective index, ratio of TD50 for neurotoxicity in ip injected albino mouse to ED50 for anticonvulsant activity in ip injected albino mouse assessed as protection against 50 mA current-induced seizure2020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Synthetic and therapeutic perspectives of nitrogen containing heterocycles as anti-convulsants.
AID1574767Therapeutic index, ratio of TD50 for neurotoxicity in po dosed mouse to ED50 for po dosed maximal electroshock induced seizure mouse model2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
Identification of 2-(2'-fluoro-[1,1'-biphenyl]-2-yl)acetamide as a Sodium Valproate-like broad spectrum anti-epileptic drug candidate.
AID682347Anticonvulsant activity in mouse assessed as protection against maximal electroshock-induced seizures at 300 mg/kg, ip after 4 hrs2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis of some novel 1-(2-naphthyl)-2-(imidazol-1-yl)ethanone oxime ester derivatives and evaluation of their anticonvulsant activity.
AID114383Tested for NMDLA induced seizures and protection against full generalized tonic seizures was recorded; Percentage of protection at 150 mg/kg per os.1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Synthesis and anticonvulsant properties of new benzylpyridazine derivatives.
AID693325Neurotoxicity in ip dosed mouse after 30 mins by rotarod test2012European journal of medicinal chemistry, Dec, Volume: 58Design, synthesis and evaluation of N-(substituted benzothiazol-2-yl)amides as anticonvulsant and neuroprotective.
AID621624Neurotoxicity in ip dosed albino CF1 mouse assessed as minimal motor coordination impairment by rotarod test2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Defining the structural parameters that confer anticonvulsant activity by the site-by-site modification of (R)-N'-benzyl 2-amino-3-methylbutanamide.
AID637074Anticonvulsant activity in ip dosed Kunming mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizure2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and anticonvulsant activity of 1-(8-(benzyloxy)quinolin-2-yl)-6-substituted-4,6-diazaspiro[2,4]heptane-5,7-diones.
AID1292569Terminal half life in healthy human (6 volunteers) at 1 g, po administered as single dose by gas liquid chromatography
AID1292545Unbound serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 14 hrs by enzyme multiple immunotechnique
AID693321Anticonvulsant activity in ip mouse assessed as protection against subcutaneous pentylenetetrazol-induced seizures2012European journal of medicinal chemistry, Dec, Volume: 58Design, synthesis and evaluation of N-(substituted benzothiazol-2-yl)amides as anticonvulsant and neuroprotective.
AID638640Anticonvulsant activity in albino CF-1 mouse assessed as protection against subcutaneous metrazol-induced seizure at 300 mg/kg, ip after 4 hrs2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Design, synthesis and anticonvulsant evaluation of novel N-(4-substituted phenyl)-2-[4-(substituted) benzylidene]-hydrazinecarbothio amides.
AID489275Neurotoxicity in Swiss albino mouse at 300 mg/kg, ip after 0.5 hrs2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Novel semicarbazones based 2,5-disubstituted-1,3,4-oxadiazoles: one more step towards establishing four binding site pharmacophoric model hypothesis for anticonvulsant activity.
AID1292557Fraction unbound in healthy human (6 volunteers) serum at 1 g, po administered as single dose measured after 5 hrs
AID443561Neurological toxicity in ip dosed albino CF1 mouse assessed as neurological impairment by rotarod test2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Synthesis and anticonvulsant activities of (R)-N-(4'-substituted)benzyl 2-acetamido-3-methoxypropionamides.
AID382387Neurotoxicity in mouse at 300 mg/kg, ip after 0.5 hrs by rotarod test2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Synthesis and CNS depressant activity of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones.
AID1292498Ratio of AUC (0 to infinity) in healthy volunteer (6 volunteers) at 800 mg, po administered as single dose to AUC (0 to infinity) in healthy volunteer (6 volunteers) at 800 mg, iv administered as single dose1978British journal of clinical pharmacology, Jun, Volume: 5, Issue:6
Disposition of sodium valproate in epileptic patients.
AID682342Anticonvulsant activity in mouse assessed as protection against maximal electroshock-induced seizures at 30 mg/kg, ip after 0.5 hrs2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis of some novel 1-(2-naphthyl)-2-(imidazol-1-yl)ethanone oxime ester derivatives and evaluation of their anticonvulsant activity.
AID263288Mortality in PTZ-induced lethal convulsions in mice at 150 mg/kg, ip2006Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
Azolylchromans as a novel scaffold for anticonvulsant activity.
AID364290Anticonvulsant activity in ip dosed mouse after 0.5 hrs by scPTZ test2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
CNS depressant and anticonvulsant activities of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones.
AID1441700Inhibition of recombinant human LTA4H Epoxide Hydrolase expressed in Escherichia coli BL21 (DE3) pLysS at 10 uM preincubated for 10 mins followed by addition of LTA4 as substrate measured after 15 mins by reverse-phase HPLC analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1563936Anticonvulsive activity in pentylenetetrazole-induced seizure albino mouse model assessed as number of clonic and tonic convulsion at 300 mg/kg, ig administered 30 mins prior to pentylenetetrazole challenge and mesured per animal for 60 mins (Rvb = 3.58 +2019European journal of medicinal chemistry, Oct-15, Volume: 180Synthesis, in vivo and in silico anticonvulsant activity studies of new derivatives of 2-(2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)acetamide.
AID1292453Elimination rate constant during beta-phase in healthy human subjects (6 subjects) at 600 mg, po administered as single enteric-coated compound dose measured by GLC method1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID114801Anticonvulsant activity in Clonic seizures when administered orally in mice1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and activity of 6-aryl-3-(hydroxypolymethyleneamino)pyridazines in animal models of epilepsy.
AID226526Protective index is the ratio between TD50 and ED50 values1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Synthesis and anticonvulsant properties of new benzylpyridazine derivatives.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID382384Anticonvulsant activity in mouse assessed as inhibition of maximal electroshock-induced seizures at 300 mg/kg, ip after 4 hrs2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Synthesis and CNS depressant activity of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones.
AID1574762Anticonvulsant activity in amygdala kindling rat model assessed as change in after discharge duration at 600 mg/kg, po (Rvb = -5.5%)2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
Identification of 2-(2'-fluoro-[1,1'-biphenyl]-2-yl)acetamide as a Sodium Valproate-like broad spectrum anti-epileptic drug candidate.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID693318Anticonvulsant activity in ip dosed mouse assessed as protection against maximal electroshock-induced seizures2012European journal of medicinal chemistry, Dec, Volume: 58Design, synthesis and evaluation of N-(substituted benzothiazol-2-yl)amides as anticonvulsant and neuroprotective.
AID190465Antagonist activity to generalized seizures kindled amygdaloid seizures in rats1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and activity of 6-aryl-3-(hydroxypolymethyleneamino)pyridazines in animal models of epilepsy.
AID1292489AUC (0 to 48 hrs) in epileptic patient (6 patients) at 800 mg, po administered as single dose by gas liquid chromatographic method1978British journal of clinical pharmacology, Jun, Volume: 5, Issue:6
Disposition of sodium valproate in epileptic patients.
AID1489016Anticonvulsant activity in amygdala kindling rat model assessed as change in after discharge threshold at 300 mg/kg, po relative to control2017Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
N-alkyl-[1,1'-biphenyl]-2-sulfonamide derivatives as novel broad spectrum anti-epileptic drugs with efficacy equivalent to that of sodium valproate.
AID765787Teratogenicity in SWV/Fnn mouse assessed as normal fetuses at 181 mg/kg, ip on day 8.5 of gestation (Rvb = 100 %)2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID1292556Fraction unbound in healthy human (6 volunteers) serum at 1 g, po administered as single dose measured after 4 hrs
AID765781Teratogenicity in SWV/Fnn mouse assessed as resorption at 301 mg/kg, ip on day 8.5 of gestation (Rvb = 6.3 %)2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID1292532Total serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 48 hrs by gas liquid chromatography
AID1489009Therapeutic index, ratio of TD50 for neurotoxicity in po dosed mouse to ED50 for po dosed 6-Hz induced seizure mouse model2017Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
N-alkyl-[1,1'-biphenyl]-2-sulfonamide derivatives as novel broad spectrum anti-epileptic drugs with efficacy equivalent to that of sodium valproate.
AID619782Anticonvulsant activity in po dosed albino Sprague-Dawley rat assessed as time of peak effect for protection against maximal electroshock seizure2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Primary amino acid derivatives: substitution of the 4'-N'-benzylamide site in (R)-N'-benzyl 2-amino-3-methylbutanamide, (R)-N'-benzyl 2-amino-3,3-dimethylbutanamide, and (R)-N'-benzyl 2-amino-3-methoxypropionamide provides potent anticonvulsants with pain
AID608518Neurotoxicity in ip dosed Kunming mouse by rotarod test2011European journal of medicinal chemistry, Jul, Volume: 46, Issue:7
Synthesis and anticonvulsant activity of 7-phenyl-6,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidin-5(4H)-ones and their derivatives.
AID1292537Unbound serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 2 hrs by enzyme multiple immunotechnique
AID639298Protective index, ratio of TD50 for neurotoxicity to ED50 for anticonvulsant activity in Swiss albino mouse2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Synthesis and anticonvulsant evaluation of some new 2,3,8-trisubstituted-4(3H)-quinazoline derivatives.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID475792Anticonvulsant activity in po dosed Sprague-Dawley rat assessed as protection against maximal electroshock-induced seizures2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Lacosamide isothiocyanate-based agents: novel agents to target and identify lacosamide receptors.
AID1574761Anticonvulsant activity in amygdala kindling rat model assessed as change in after discharge duration at 300 mg/kg, po (Rvb = -5.5%)2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
Identification of 2-(2'-fluoro-[1,1'-biphenyl]-2-yl)acetamide as a Sodium Valproate-like broad spectrum anti-epileptic drug candidate.
AID639222Anticonvulsant activity in Swiss albino mouse assessed as protection against PTZ-induced clonic seizure at 300 mg/kg, ip administered 30 mins before challenge2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Synthesis and anticonvulsant evaluation of some new 2,3,8-trisubstituted-4(3H)-quinazoline derivatives.
AID395124Anticonvulsant activity in mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures at 20 mg/kg, po2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Synthesis and potential anticonvulsant activity of new N-3-substituted 5,5-cyclopropanespirohydantoins.
AID40039Antagonist activity to generalized seizures Photically induced seizures in senegalese Papio papio baboons1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and activity of 6-aryl-3-(hydroxypolymethyleneamino)pyridazines in animal models of epilepsy.
AID545528Anticonvulsant activity in ip dosed mouse assessed as inhibition of PTZ-induced clonic seizure2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Synthesis and anticonvulsant activity of N-3-arylamide substituted 5,5-cyclopropanespirohydantoin derivatives.
AID1143175Anticonvulsant activity in Swiss albino mouse assessed as seizure latency to onset of clonus at 200 mg/kg, po administered 60 mins prior to pentylenetetrazole challenge (Rvb = 1.54 +/- 0.90 mins)2014European journal of medicinal chemistry, Jun-10, Volume: 80Anticonvulsant evaluation of clubbed indole-1,2,4-triazine derivatives: a synthetic approach.
AID619698Toxicity in po dosed albino Sprague-Dawley rat assessed as behavioural toxicity2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Primary amino acid derivatives: substitution of the 4'-N'-benzylamide site in (R)-N'-benzyl 2-amino-3-methylbutanamide, (R)-N'-benzyl 2-amino-3,3-dimethylbutanamide, and (R)-N'-benzyl 2-amino-3-methoxypropionamide provides potent anticonvulsants with pain
AID1292530Total serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 30 hrs by gas liquid chromatography
AID545529Toxicity against ip dosed mouse2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Synthesis and anticonvulsant activity of N-3-arylamide substituted 5,5-cyclopropanespirohydantoin derivatives.
AID1292440Plasma concentration in healthy human subjects (6 subjects) at 600 mg, po administered as single enteric-coated compound dose measured after 0.5 hrs by GLC method1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID382368Anticonvulsant activity in ip dosed mouse assessed as inhibition of pentylenetetrazole-induced seizure after 0.5 hrs2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Synthesis and CNS depressant activity of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones.
AID1292572fAUC in healthy human (6 volunteers) at 1 g, po administered as single dose by gas liquid chromatography
AID750672Neurotoxicity in ip dosed albino CF-1 mouse assessed as minimal motor impairment in half or more animals after 0.5 hrs by rotarod test2013European journal of medicinal chemistry, Jun, Volume: 64Augmentation of GABAergic neurotransmission by novel N-(substituted)-2-[4-(substituted)benzylidene]hydrazinecarbothioamides-a potential anticonvulsant approach.
AID688843Neurotoxicity in Swiss albino mouse assessed as inability to climb up backwards in a glass tube within 30 seconds at 1.38 mmol/kg, ip measured after 15 and 25 mins by Chimney test2011European journal of medicinal chemistry, Nov, Volume: 46, Issue:11
Synthesis and anticonvulsant activity of some new thiazolo[3,2-a][1,3]diazepine, benzo[d]thiazolo[5,2-a][12,6]diazepine and benzo[d]oxazolo[5,2-a][12,6]diazepine analogues.
AID1292568Cmax in healthy human (6 volunteers) at 1 g, po administered as single dose by gas liquid chromatography
AID665864Anticonvulsant activity in ip dosed NMRI mouse assessed as protection against maximal electroshock-induced seizure after 30 mins postdose2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Synthesis, anticonvulsant activity, and neuropathic pain-attenuating activity of N-benzyl 2-amino-2-(hetero)aromatic acetamides.
AID263286Hind limb tonic extension in PTZ-induced lethal convulsions in mice at 150 mg/kg, ip2006Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
Azolylchromans as a novel scaffold for anticonvulsant activity.
AID1074411Neurotoxicity in KunMing mouse assessed as motor impairment at 300 mg/kg, ip after 4 hrs by rotarod test2014European journal of medicinal chemistry, Feb-12, Volume: 73Design, synthesis and evaluation of the antidepressant and anticonvulsant activities of triazole-containing quinolinones.
AID1161064Anticonvulsant activity in ip dosed Sprague-Dawley rat assessed as protection against maximal electroshock-induced seizures2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Novel fluorinated pyrrolo[1,2-a]pyrazine-2,6-dione derivatives: synthesis and anticonvulsant evaluation in animal models of epilepsy.
AID1292450Plasma concentration in healthy human subjects (6 subjects) at 600 mg, po administered as single enteric-coated compound dose measured after 72 hrs by GLC method1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID489288Anticonvulsant activity against maximal electroshock-induced seizures in ip dosed Swiss albino mouse assessed as minimum effective dose after 0.5 hrs2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Novel semicarbazones based 2,5-disubstituted-1,3,4-oxadiazoles: one more step towards establishing four binding site pharmacophoric model hypothesis for anticonvulsant activity.
AID1177950Anticonvulsant activity in mouse assessed as reduction of maximal electroshock-induced seizures2014European journal of medicinal chemistry, Apr-09, Volume: 76Recent advances in the structural library of functionalized quinazoline and quinazolinone scaffolds: synthetic approaches and multifarious applications.
AID1292522Total serum concentration in healthy human (6 volunteers) at 1 g, po administered as single dose measured after 4 hrs by gas liquid chromatography
AID569162Anticonvulsant activity in albino CF-1 mouse assessed as protection against maximal electroshock-induced seizures at 300 mg/kg, ip after 4 hrs2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Design & synthesis of N'-[substituted] pyridine-4-carbohydrazides as potential anticonvulsant agents.
AID387784Anticonvulsant activity in ip dosed albino mouse by MES seizure test2008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Synthesis and anticonvulsant activities of N-benzyl (2R)-2-acetamido-3-oxysubstituted propionamide derivatives.
AID569077Anticonvulsant activity in albino CF-1 mouse assessed as protection against maximal electroshock-induced seizures at 300 mg/kg, ip after 0.5 hrs2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Design & synthesis of N'-[substituted] pyridine-4-carbohydrazides as potential anticonvulsant agents.
AID1574766Neurotoxicity in po dosed mouse by rotarod test2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
Identification of 2-(2'-fluoro-[1,1'-biphenyl]-2-yl)acetamide as a Sodium Valproate-like broad spectrum anti-epileptic drug candidate.
AID1292566Fraction unbound in healthy human (6 volunteers) serum at 1 g, po administered as single dose measured after 48 hrs
AID1292457Apparent volume of distribution in healthy human subjects (6 subjects) at 600 mg, po administered as single enteric-coated compound dose measured by GLC method1977European journal of clinical pharmacology, Oct-14, Volume: 12, Issue:2
Disposition of valproic acid in man.
AID1292490AUC (0 to infinity) in epileptic patient (6 patients) at 800 mg, po administered as single dose by gas liquid chromatographic method1978British journal of clinical pharmacology, Jun, Volume: 5, Issue:6
Disposition of sodium valproate in epileptic patients.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (80)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (6.25)18.7374
1990's4 (5.00)18.2507
2000's14 (17.50)29.6817
2010's49 (61.25)24.3611
2020's8 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.22%)5.53%
Reviews4 (4.88%)6.00%
Case Studies1 (1.22%)4.05%
Observational0 (0.00%)0.25%
Other76 (92.68%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]